


**CUMULATIVE
SUPPLEMENT 5
May 2011**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Cumulative Supplement 5

May 2011

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**CUMULATIVE SUPPLEMENT 5
May 2011**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2010</u>	<u>MAR 2011</u>	<u>JUN 2011</u>	<u>SEPT 2011</u>	<u>DEC 2011</u>
DRUG PRODUCTS LISTED	13838	14029			
SINGLE SOURCE	2482	2477			
	(17.9%)	(17.7%)			
MULTISOURCE	11267	11463			
	(81.4%)	(81.7%)			
THERAPEUTICALLY EQUIVALENT	11107	11301			
	(80.3%)	(80.6%)			
NOT THERAPEUTICALLY EQUIVALENT	160	162			
	(1.2%)	(1.2%)			
EXCEPTIONS ¹	89	89			
	(0.6%)	(0.6%)			
NEW MOLECULAR ENTITIES APPROVED	8	6			
NUMBER OF APPLICANTS	752	768			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.
CPOT Change. Potency amount/unit.
CRLD Change. Reference Listed Drug.
CTEC Change. Therapeutic Equivalence Code.
CTNA Change. Trade Name.
DISC Discontinued. The Rx or OTC listed product is not
being marketed and will be moved to the discontinued
section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 31ST EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

1-1

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

+ CENTOCOR ORTHO 250MG N202379 001 Apr 28, 2011 Apr NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA MIRROR PHARMS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar CAHN

AA 500MG;50MG;40MG A040883 001 Dec 23, 2008 Mar CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA WRASER PHARMS LLC 356.4MG;30MG;16MG A040688 001 Apr 03, 2007 Jan CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA BOCA PHARMA 300MG;5MG A090415 001 Jan 24, 2011 Feb CTEC

AB 300MG;5MG A090415 001 Jan 24, 2011 Jan NEWA

AA 300MG;7.5MG A090415 002 Jan 24, 2011 Feb CTEC

AB 300MG;7.5MG A090415 002 Jan 24, 2011 Jan NEWA

AA 300MG;10MG A090415 003 Jan 24, 2011 Feb CTEC

AB 300MG;10MG A090415 003 Jan 24, 2011 Jan NEWA

AA + MIKART 300MG;5MG A040658 001 Jan 19, 2006 Mar CRLD

AA 300MG;5MG A040658 001 Jan 19, 2006 Feb CTEC

AA + 300MG;7.5MG A040556 002 Mar 24, 2006 Feb CTEC

AA + 300MG;10MG A040556 001 Jun 23, 2004 Feb CTEC

>D> AA RANBAXY 325MG;10MG A040826 001 Aug 16, 2007 May DISC

>D> AA 500MG;5MG A040825 001 Aug 16, 2007 May DISC

>A> @ 500MG;5MG A040825 001 Aug 16, 2007 May DISC

>D> AA 500MG;10MG A040824 001 Aug 16, 2007 May DISC

>A> @ 500MG;10MG A040824 001 Aug 16, 2007 May DISC

>D> AA 750MG;7.5MG A040822 001 Aug 16, 2007 May DISC

>A> @ RANBAXY LABS LTD 325MG;10MG A040826 001 Aug 16, 2007 May DISC

>A> @ 750MG;7.5MG A040822 001 Aug 16, 2007 May DISC

LORTAB

AA UCB INC 500MG;5MG A087722 001 Jul 09, 1982 Jan CAHN

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

@ VINTAGE PHARMS 650MG;65MG A040507 001 Jul 30, 2003 Mar DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

@ XANODYNE PHARM 650MG;100MG N017122 002 Jan DISC

DARVOCET-N 50

@ XANODYNE PHARM 325MG;50MG N017122 001 Jan DISC

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

@ CORNERSTONE 325MG;100MG A076743 001 May 07, 2004 Mar DISC

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	@ CORNERSTONE	500MG;100MG	A076750	001	Jun 28, 2004	Mar	DISC
	@ MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008	Apr	DISC
AB		650MG;100MG	A077821	001	Feb 11, 2008	Mar	CAHN
	@ TEVA	650MG;100MG	A074119	001	Dec 19, 1994	Mar	DISC
	@ VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001	Mar	DISC
	@	650MG;100MG	A074843	001	Feb 12, 1997	Mar	DISC

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB	MYLAN	200MG	A074977	001	Apr 13, 1998	Feb	CAHN
----	-------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

AB	MYLAN	400MG	A074976	001	Apr 13, 1998	Feb	CAHN
AB		800MG	A074976	002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

	@ HOSPIRA	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999	Feb	DISC
--	-----------	-----------------	---------	-----	--------------	-----	------

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

ACYCLOVIR AND HYDROCORTISONE

>D>							
>D>	+	MEDA PHARMS	5%;1%	N022436	001	Jul 31, 2009	May CTNA
>A>		XERESE					
>A>	+	MEDA PHARMS	5%;1%	N022436	001	Jul 31, 2009	May CTNA

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL

ACLOVATE

AB	+	NYCOMED US	0.05%	N018702	001	Dec 14, 1982	Mar CAHN
----	---	------------	-------	---------	-----	--------------	----------

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB	MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Feb	CAHN
AB		EQ 70MG BASE	A078638	002	Aug 04, 2008	Feb	CAHN
	@ SANDOZ	EQ 5MG BASE	A075871	001	Apr 22, 2009	Mar	DISC
	@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Mar	DISC
	@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Mar	DISC
	@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Mar	DISC
	@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Mar	DISC

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011	Feb	NEWA
AB		300MG	A090637	002	Mar 16, 2011	Feb	NEWA

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

>A>	AB	AUROBINDO PHARMA USA	0.5MG	A090871	001	Jun 07, 2011	May NEWA
-----	----	----------------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

>A>	AB	AUROBINDO PHARMA USA	1MG	A090871 002	Jun 07, 2011	May	NEWA
>A>	AB		2MG	A090871 003	Jun 07, 2011	May	NEWA
>A>	AB		3MG	A090871 004	Jun 07, 2011	May	NEWA

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

>A>		MEDA PHARMS	0.125MG	N020700 001	Nov 19, 1996	May	CAHN
>A>			0.25MG	N020700 002	Nov 19, 1996	May	CAHN
>A>			0.5MG	N020700 003	Nov 19, 1996	May	CAHN
>A>	+		1MG	N020700 004	Nov 19, 1996	May	CAHN
>D>		VIVUS	0.125MG	N020700 001	Nov 19, 1996	May	CAHN
>D>			0.25MG	N020700 002	Nov 19, 1996	May	CAHN
>D>			0.5MG	N020700 003	Nov 19, 1996	May	CAHN
>D>	+		1MG	N020700 004	Nov 19, 1996	May	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>D>	AB	ACTAVIS TOTOWA	EQ 2.5MG BASE	A078131 001	Sep 04, 2007	May	CAHN
>D>	AB		EQ 5MG BASE	A078131 002	Sep 04, 2007	May	CAHN
>D>	AB		EQ 10MG BASE	A078131 003	Sep 04, 2007	May	CAHN
	AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552 001	Apr 08, 2009	Apr	CAHN
	AB		EQ 5MG BASE	A078552 002	Apr 08, 2009	Apr	CAHN
	AB		EQ 10MG BASE	A078552 003	Apr 08, 2009	Apr	CAHN
	AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771 001	Apr 12, 2011	Mar	NEWA
	AB		EQ 5MG BASE	A077771 002	Apr 12, 2011	Mar	NEWA
	AB		EQ 10MG BASE	A077771 003	Apr 12, 2011	Mar	NEWA
>A>	AB	PURACAP PHARM	EQ 2.5MG BASE	A078131 001	Sep 04, 2007	May	CAHN
>A>	AB		EQ 5MG BASE	A078131 002	Sep 04, 2007	May	CAHN
>A>	AB		EQ 10MG BASE	A078131 003	Sep 04, 2007	May	CAHN
	AB	SECAN PHARMS	EQ 5MG BASE	A090752 001	Apr 15, 2011	Apr	NEWA
	AB		EQ 10MG BASE	A090752 002	Apr 15, 2011	Apr	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

AB		NOVARTIS	EQ 5MG BASE;40MG	N020364 007	Apr 11, 2006	Jan	CFTG
AB	+		EQ 10MG BASE;40MG	N020364 006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB		AM ANTIBIOTICS	250MG	A062058 001		Feb	CDFR
AB			500MG	A062058 002		Feb	CDFR

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+		DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824 001	Feb 08, 2011	Feb	NEWA
---	--	-----------------	--	-------------	--------------	-----	------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349 001	Sep 20, 2010	Apr	CAIN
AP		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340 001	Sep 20, 2010	Apr	CAIN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340 002	Sep 20, 2010	Apr	CAIN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349 002	Sep 20, 2010	Apr	CAIN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339 001	Sep 20, 2010	Apr	CAIN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	SANTOS BIOTECH	1MG	A078944 001	Jun 28, 2010	Feb	CAHN
----	----------------	-----	-------------	--------------	-----	------

ARGATROBAN

>A> INJECTABLE; IV (INFUSION)

>A> ARGATROBAN IN SODIUM CHLORIDE

>A>	+ SANDOZ	125MG/125ML (1MG/ML)	N022485 001	May 09, 2011	May	NEWA
-----	----------	----------------------	-------------	--------------	-----	------

>D> SOLUTION; IV (INFUSION)

>D> ARGATROBAN IN DEXTROSE

>A>	@ SANDOZ	125MG/125ML (1MG/ML)	N201743 001	May 09, 2011	May	DISC
-----	----------	----------------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	MIRROR PHARMS	325MG;200MG	A040832 001	Jan 07, 2010	Mar	CAHN
AB	PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	MIRROR PHARMS	325MG;200MG;16MG	A040860 001	Jan 07, 2010	Mar	CAHN
AB	PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	COASTAL PHARMS	325MG;4.8355MG	A091670 001	Mar 16, 2011	Feb	NEWA
AA	WATSON LABS	325MG;4.8355MG	A090084 001	Mar 22, 2011	Mar	NEWA
PERCODAN						
AA	+ ENDO PHARMS	325MG;4.8355MG	N007337 007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MYLAN	25MG	A074126 003	Aug 26, 1998	Feb	CAHN
AB		50MG	A074126 001	Mar 23, 1994	Feb	CAHN
AB		100MG	A074126 002	Mar 23, 1994	Feb	CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	250MG;100MG	A091211 001	Jan 12, 2011	Jan	NEWA
----	-------------------	-------------	-------------	--------------	-----	------

TABLET; ORAL								
MALARONE								
AB	+	GLAXOSMITHKLINE	250MG;100MG	N021078	001	Jul 14, 2000	Jan	CFTG
<u>AZILSARTAN MEDOXOMIL</u>								
TABLET; ORAL								
EDARBI								
		TAKEDA PHARMS	40MG	N200796	001	Feb 25, 2011	Feb	NEWA
	+		80MG	N200796	002	Feb 25, 2011	Feb	NEWA
<u>AZTREONAM</u>								
INJECTABLE; INJECTION								
AZTREONAM								
AP		BEDFORD	1GM/VIAL	A065286	001	Mar 23, 2011	Mar	NEWA
AP			2GM/VIAL	A065286	002	Mar 23, 2011	Mar	NEWA
<u>BACITRACIN</u>								
OINTMENT; OPHTHALMIC								
BACITRACIN								
	+	FERA PHARMS	500 UNITS/GM	A061212	001		Feb	CAHN
	+	NYCOMED US	500 UNITS/GM	A061212	001		Jan	CAHN
<u>BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>								
OINTMENT; OPHTHALMIC								
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC								
AT		FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Feb	CAHN
AT		NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Jan	CAHN
<u>BACITRACIN ZINC; POLYMYXIN B SULFATE</u>								
OINTMENT; OPHTHALMIC								
BACITRACIN ZINC AND POLYMYXIN B SULFATE								
AT		FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Feb	CAHN
AT		NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jan	CAHN
<u>BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>								
OINTMENT; OPHTHALMIC								
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE								
	+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Feb	CAHN
	+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Jan	CAHN
<u>BACLOFEN</u>								
INJECTABLE; INTRATHECAL								
GABLOFEN								
AP		CNS THERAPS INC	0.05MG/ML	N022462	001	Nov 19, 2010	Feb	CTEC
AP			0.5MG/ML	N022462	002	Nov 19, 2010	Feb	CTEC
AP			2MG/ML	N022462	003	Nov 19, 2010	Feb	CTEC
Lioresal								
AP	+	MEDTRONIC	0.05MG/ML	N020075	003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075	002	Jun 17, 1992	Feb	CTEC
TABLET; ORAL								
BACLOFEN								
AB		PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	20MG	A077088 001	Oct 31, 2007	Feb	CAHN
----	-------------	------	-------------	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

>D>	AB	HUAHAI US INC	5MG	A076118 001	Feb 11, 2004	May	CAHN
>D>	AB		10MG	A076118 002	Feb 11, 2004	May	CAHN
>D>	AB		20MG	A076118 003	Feb 11, 2004	May	CAHN
>D>	AB		40MG	A076118 004	Feb 11, 2004	May	CAHN
>A>	AB	PRINSTON PHARM LLC	5MG	A076118 001	Feb 11, 2004	May	CAHN
>A>	AB		10MG	A076118 002	Feb 11, 2004	May	CAHN
>A>	AB		20MG	A076118 003	Feb 11, 2004	May	CAHN
>A>	AB		40MG	A076118 004	Feb 11, 2004	May	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	5MG;6.25MG	A076612 001	Feb 11, 2004	Feb	CAHN
AB		10MG;12.5MG	A076612 002	Feb 11, 2004	Feb	CAHN
AB		20MG;12.5MG	A076612 003	Feb 11, 2004	Feb	CAHN
AB		20MG;25MG	A076612 004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP	LUITPOLD	1MG/ML	A091152 001	Mar 29, 2010	Feb	CAHN
----	----------	--------	-------------	--------------	-----	------

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB	STI PHARMA LLC	EQ 0.1% BASE	A070052 001	Jul 31, 1985	Apr	CAHN
----	----------------	--------------	-------------	--------------	-----	------

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	ROXANE	50MG	A078285 001	Mar 24, 2011	Mar	NEWA
----	--------	------	-------------	--------------	-----	------

>A> BOCEPREVIR

>A> CAPSULE; ORAL

>A> VICTRELIS

>A>	+	SCHERING	200MG	N202258 001	May 13, 2011	May	NEWA
-----	---	----------	-------	-------------	--------------	-----	------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

+	ISTA PHARMS INC	0.09%	N021664 002	Oct 16, 2010	Mar	CRLD
---	-----------------	-------	-------------	--------------	-----	------

BROMFENAC SODIUM

	COASTAL PHARMS	0.09%	A201211 001	May 11, 2011	Apr	NEWA
--	----------------	-------	-------------	--------------	-----	------

XIBROM

@	ISTA PHARMS INC	0.09%	N021664 001	Mar 24, 2005	Mar	DISC
---	-----------------	-------	-------------	--------------	-----	------

BUDESONIDE

CAPSULE; ORAL

>A>		BUDESONIDE							
>A>	AB	MYLAN	3MG	A090410	001	May 16, 2011	May	NEWA	
		ENTOCORT EC							
>D>	+	ASTRAZENECA	3MG	N021324	001	Oct 02, 2001	May	CFTG	
>A>	AB	+	3MG	N021324	001	Oct 02, 2001	May	CFTG	

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>A>	AB1	ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	May	NEWA	
>A>	AB1		150MG	A091459	002	Jun 09, 2011	May	NEWA	
>A>	AB2		150MG	A091520	001	Jun 09, 2011	May	NEWA	
>A>	AB1		200MG	A091459	003	Jun 09, 2011	May	NEWA	
>D>	AB1	WATSON LABS	100MG	A079095	001	Mar 24, 2009	May	CAHN	
>D>	AB1		150MG	A079095	002	Mar 24, 2009	May	CAHN	
>D>	AB2		150MG	A079094	001	Mar 24, 2009	May	CAHN	
>D>	AB1		200MG	A079095	003	Mar 24, 2009	May	CAHN	
>A>	AB1	WATSON LABS FLORIDA	100MG	A079095	001	Mar 24, 2009	May	CAHN	
>A>	AB2		150MG	A079094	001	Mar 24, 2009	May	CAHN	
>A>	AB1		150MG	A079095	002	Mar 24, 2009	May	CAHN	
>A>	AB1		200MG	A079095	003	Mar 24, 2009	May	CAHN	

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

AT		G AND W LABS INC	0.005%	A078468	001	Mar 24, 2011	Mar	NEWA	
----	--	------------------	--------	---------	-----	--------------	-----	------	--

CALCIUM ACETATE

SOLUTION; ORAL

PHOSLYRA

+		FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N022581	001	Apr 18, 2011	Apr	NEWA	
---	--	-----------------	----------------------	---------	-----	--------------	-----	------	--

TABLET; ORAL

CALCIUM ACETATE

AB		PADDOCK LABS	EQ 169MG CALCIUM	A091561	001	Apr 13, 2011	Mar	NEWA	
----	--	--------------	------------------	---------	-----	--------------	-----	------	--

ELIPHOS

AB	+	CYPRESS PHARM	EQ 169MG CALCIUM	A078502	001	Nov 25, 2008	Mar	CTEC	
----	---	---------------	------------------	---------	-----	--------------	-----	------	--

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

>D>	AB	HUAHAI US INC	12.5MG	A074477	001	Feb 13, 1996	May	CAHN	
>D>	AB		25MG	A074477	002	Feb 13, 1996	May	CAHN	
>D>	AB		50MG	A074477	003	Feb 13, 1996	May	CAHN	
>D>	AB		100MG	A074477	004	Feb 13, 1996	May	CAHN	
>A>	AB	PRINSTON PHARM LLC	12.5MG	A074477	001	Feb 13, 1996	May	CAHN	
>A>	AB		25MG	A074477	002	Feb 13, 1996	May	CAHN	
>A>	AB		50MG	A074477	003	Feb 13, 1996	May	CAHN	
>A>	AB		100MG	A074477	004	Feb 13, 1996	May	CAHN	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

>A>	AB	NOSTRUM	100MG	A076697	001	May 20, 2011	May	NEWA	
-----	----	---------	-------	---------	-----	--------------	-----	------	--

<u>CAPSULE, EXTENDED RELEASE; ORAL</u>						
>A>		CARBAMAZEPINE				
>A>	AB	NOSTRUM	200MG	A076697 002	May 20, 2011	May NEWA
>A>	AB		300MG	A076697 003	May 20, 2011	May NEWA
<u>CARBATROL</u>						
>D>		SHIRE	100MG	N020712 003	Sep 30, 1997	May CFTG
>A>	AB		100MG	N020712 003	Sep 30, 1997	May CFTG
>D>			200MG	N020712 001	Sep 30, 1997	May CFTG
>A>	AB		200MG	N020712 001	Sep 30, 1997	May CFTG
>D>	+		300MG	N020712 002	Sep 30, 1997	May CFTG
>A>	AB	+	300MG	N020712 002	Sep 30, 1997	May CFTG
<u>TABLET, CHEWABLE; ORAL</u>						
<u>CARBAMAZEPINE</u>						
		@ JUBILANT CADISTA	100MG	A071940 001	Feb 01, 1988	Jan CAHN
<u>CARBIDOPA; LEVODOPA</u>						
<u>TABLET; ORAL</u>						
<u>SINEMET</u>						
AB		MERCK SHARP DOHME	10MG;100MG	N017555 001		Jan CAHN
AB			25MG;100MG	N017555 003		Jan CAHN
AB	+		25MG;250MG	N017555 002		Jan CAHN
<u>TABLET, EXTENDED RELEASE; ORAL</u>						
<u>SINEMET CR</u>						
AB		MERCK SHARP DOHME	25MG;100MG	N019856 002	Dec 24, 1992	Jan CAHN
AB	+		50MG;200MG	N019856 001	May 30, 1991	Jan CAHN
<u>CARBINOXAMINE MALEATE</u>						
<u>TABLET; ORAL</u>						
<u>CARBINOXAMINE MALEATE</u>						
>A>	AA	RIVERS EDGE PHARMS	4MG	A090756 001	May 27, 2011	May NEWA
<u>CARISOPRODOL</u>						
<u>TABLET; ORAL</u>						
<u>CARISOPRODOL</u>						
AA		MIRROR PHARMS	350MG	A040823 001	Oct 22, 2008	Mar CAHN
AA		PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb CAHN
<u>CEFAZOLIN SODIUM</u>						
<u>INJECTABLE; INJECTION</u>						
<u>CEFAZOLIN SODIUM</u>						
AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005	Jan CAHN
AP			EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005	Jan CAHN
AP			EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005	Jan CAHN
AP			EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005	Jan CAHN
<u>CEFEPIME HYDROCHLORIDE</u>						
<u>INJECTABLE; INJECTION</u>						
<u>CEFEPIME HYDROCHLORIDE</u>						
AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065369 001	Jun 18, 2007	Jan CAHN
AP			EQ 1GM BASE/VIAL	A065369 002	Jun 18, 2007	Jan CAHN
AP			EQ 2GM BASE/VIAL	A065369 003	Jun 18, 2007	Jan CAHN
<u>CEFOTAXIME SODIUM</u>						
<u>INJECTABLE; INJECTION</u>						
<u>CEFOTAXIME SODIUM</u>						
AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065290 001	Aug 11, 2006	Jan CAHN

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065290 002	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065293 001	Aug 10, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065290 003	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065293 002	Aug 10, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065292 001	Aug 10, 2006	Jan	CAHN

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313 001	Jan 23, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065313 002	Jan 23, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065312 001	Feb 13, 2006	Jan	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	+ SANDOZ	EQ 200MG BASE	A065462 002	May 28, 2008	Jan	CRLD
	VANTIN					
	@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674 001	Aug 07, 1992	Jan	DISC
	@	EQ 200MG BASE	N050674 002	Aug 07, 1992	Jan	DISC

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230 001	Aug 02, 2005	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A065230 002	Aug 02, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065230 003	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065230 004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTION

CEFTRIAZONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065232 001	Aug 02, 2005	Jan	CAHN
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A065168 001	May 17, 2005	Jan	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

>D>	AB	ALKEM	EQ 250MG BASE	A065496 001	Jun 07, 2010	May	CAHN
>D>	AB		EQ 500MG BASE	A065496 002	Jun 07, 2010	May	CAHN
>A>	AB	ALKEM LABS LTD	EQ 250MG BASE	A065496 001	Jun 07, 2010	May	CAHN
>A>	AB		EQ 500MG BASE	A065496 002	Jun 07, 2010	May	CAHN

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048 001	Jan 09, 2004	Mar	CTEC
AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

	@ ACS DOBFAR	EQ 100MG BASE/ML	A062117 001		Jan	CAHN
AB		EQ 125MG BASE/5ML	A062117 002		Jan	CAHN
AB	+	EQ 250MG BASE/5ML	A062117 003		Jan	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	LYNE	0.12%	A074291 001	Dec 28, 1995	Feb	CAHN
----	------	-------	-------------	--------------	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621 001	Jan 21, 2011	Jan	NEWA
AA		EQ 300MG BASE	A090612 001	Jan 21, 2011	Jan	NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074557 001	Aug 15, 1996	Apr	CRLD
		CHOLESTYRAMINE LIGHT					
AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074558 001	Aug 15, 1996	Apr	CRLD
		QUESTRAN					
		@ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N016640 001		Apr	DISC
		@	EQ 4GM RESIN/SCOOPFUL	N016640 003		Apr	DISC
		QUESTRAN LIGHT					
		@ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Apr	DISC
		@	EQ 4GM RESIN/SCOOPFUL	N019669 003	Dec 05, 1988	Apr	DISC
AB	+		EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Mar	CRLD

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT	TARO	1%	A090269 001	Feb 23, 2011	Feb	NEWA
----	------	----	-------------	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

>D>							
>D>	+	DEPOMED INC	EQ 500MG BASE	N021744 001	May 19, 2005	May	DISC
>A>		@	EQ 500MG BASE	N021744 001	May 19, 2005	May	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	MYLAN	EQ 10MG BASE	A077042 001	Nov 05, 2004	Apr	CAHN
AB		EQ 20MG BASE	A077042 002	Nov 05, 2004	Apr	CAHN
AB		EQ 40MG BASE	A077042 003	Nov 05, 2004	Apr	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

>A>	AB	MATRIX LABS LTD	EQ 75MG BASE	A091225 001	May 31, 2011	May	NEWA
>A>	AB		EQ 150MG BASE	A091225 002	May 31, 2011	May	NEWA

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

>A>	AB	MATRIX LABS LTD	EQ 300MG BASE	A091225 003	May 31, 2011	May	NEWA
-----	----	-----------------	---------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAGEL

BT	+	GALDERMA LABS LP	EQ 1% BASE	N050782 001	Nov 27, 2000	Mar	CRLD
----	---	------------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@ COREPHARMA

EQ 1% BASE

A064108 001	Sep 27, 1996	Apr	CAHN
-------------	--------------	-----	------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

OLUX

>D>	AB	+	CONNETICS	0.05%	N021142 001	May 26, 2000	May	CAHN
-----	----	---	-----------	-------	-------------	--------------	-----	------

>A>	AB	+	STIEFEL LABS INC	0.05%	N021142 001	May 26, 2000	May	CAHN
-----	----	---	------------------	-------	-------------	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@ COREPHARMA

0.05%

A075338 001	Feb 09, 2001	Apr	CAHN
-------------	--------------	-----	------

CLOBETASOL PROPIONATE (EMOLLIENT)

@ COREPHARMA

0.05%

A075733 001	Aug 22, 2001	Apr	CAHN
-------------	--------------	-----	------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

@ COREPHARMA

0.05%

A075057 001	Aug 12, 1998	Apr	CAHN
-------------	--------------	-----	------

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

>A>	AB	ACTAVIS MID ATLANTIC	0.05%	A078854 001	Jun 07, 2011	May	NEWA
-----	----	----------------------	-------	-------------	--------------	-----	------

CLOBEX

>D>	+	GALDERMA LABS	0.05%	N021644 001	Feb 05, 2004	May	CFTG
-----	---	---------------	-------	-------------	--------------	-----	------

>A>	AB	+		0.05%	N021644 001	Feb 05, 2004	May	CFTG
-----	----	---	--	-------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

NYCOMED US

0.05%

A075391 001	Feb 08, 1999	Apr	CAHN
-------------	--------------	-----	------

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

>A>		PADDOCK LABS	0.05%	A090898 001	Jun 16, 2011	May	NEWA
-----	--	--------------	-------	-------------	--------------	-----	------

CLOBEX

>D>	+	GALDERMA LABS LP	0.05%	N021835 001	Oct 27, 2005	May	CFTG
-----	---	------------------	-------	-------------	--------------	-----	------

>A>	+		0.05%	N021835 001	Oct 27, 2005	May	CFTG
-----	---	--	-------	-------------	--------------	-----	------

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP		WEST WARD	1MG/10ML (0.1MG/ML)	A200300 001	Jan 26, 2011	Jan	NEWA
----	--	-----------	---------------------	-------------	--------------	-----	------

AP			5MG/10ML (0.5MG/ML)	A200300 002	Jan 26, 2011	Jan	NEWA
----	--	--	---------------------	-------------	--------------	-----	------

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

AB		MIRROR PHARMS	0.5MG;500MG	A040618 001	May 13, 2008	Mar	CAHN
----	--	---------------	-------------	-------------	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB		ANESTA AG	15MG	N021777 001	Feb 01, 2007	Apr	CFTG
----	--	-----------	------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB	+	ANESTA AG	30MG	N021777	002	Feb 01, 2007	Apr	CFTG
CYCLOBENZAPRINE HYDROCHLORIDE								
AB		MYLAN	15MG	A090738	001	Apr 18, 2011	Apr	NEWA
AB			30MG	A090738	002	Apr 18, 2011	Apr	NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006	Jan	CAHN
AB			10MG	A077563	002	Apr 19, 2006	Jan	CAHN
AB		KVK TECH	5MG	A078048	001	Feb 28, 2011	Feb	NEWA
AB			10MG	A078048	002	Feb 28, 2011	Feb	NEWA
AB		PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
AB			10MG	A077209	001	Oct 04, 2005	Feb	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

>D>		NOVARTIS	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	May	CAHN
>D>	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	May	CAHN
>A>		WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	May	CAHN
>A>	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	May	CAHN

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

>D>		TIBOTEC	EQ 300MG BASE	N021976	001	Jun 23, 2006	May	DISC
>A>	@		EQ 300MG BASE	N021976	001	Jun 23, 2006	May	DISC

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

>A>	@	COREPHARMA	75MG	N050261	001		May	CAHN
>A>	AB		150MG	N050261	002		May	CAHN
>A>	AB	+	300MG	N050261	003		May	CAHN
>D>	@	STIEFEL	75MG	N050261	001		May	CAHN
>D>	AB		150MG	N050261	002		May	CAHN
>D>	AB	+	300MG	N050261	003		May	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

>D>	AB	COVENANT PHARMA INC	150MG	A065389	001	Dec 01, 2008	May	CAHN
>D>	AB		300MG	A065389	002	Dec 01, 2008	May	CAHN
>A>	AB	VERSAPHARM	150MG	A065389	001	Dec 01, 2008	May	CAHN
>A>	AB		300MG	A065389	002	Dec 01, 2008	May	CAHN

DESLORATADINE

TABLET; ORAL

DESLORATADINE

AB		DR REDDYS LABS LTD	5MG	A078365	001	Mar 08, 2011	Feb	NEWA
----	--	--------------------	-----	---------	-----	--------------	-----	------

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

AB	+	SCHERING	5MG;240MG	N021605	001	Mar 03, 2005	Apr	CFTG
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR								
AB		DR REDDYS LABS LTD	5MG;240MG	A078366	001	Apr 26, 2011	Apr	NEWA

DESMOPRESSIN ACETATE

	SPRAY, METERED; NASAL						
>D>	STIMATE						
>D>	+ CSL BEHRING	0.15MG/SPRAY		N020355	001	Mar 07, 1994	May DISC
>A>	@	0.15MG/SPRAY		N020355	001	Mar 07, 1994	May DISC

DESOGESTREL; ETHINYL ESTRADIOL

	TABLET; ORAL-28						
	EMOQUETTE						
AB	VINTAGE	0.15MG;0.03MG		A076675	001	Feb 25, 2011	Feb NEWA

DESOXIMETASONE

	GEL; TOPICAL						
	DESOXIMETASONE						
AB	VERSAPHARM	0.05%		A090727	001	Mar 10, 2011	Feb NEWA
	OINTMENT; TOPICAL						
	TOPICORT						
>D>	@ TARO PHARMS NORTH	0.05%		N018594	001	Jan 17, 1985	May CMFD
>A>	+	0.05%		N018594	001	Jan 17, 1985	May CMFD

DEXAMETHASONE

	ELIXIR; ORAL						
	DEXAMETHASONE						
AA	VINTAGE PHARMS	0.5MG/5ML		A091188	001	May 11, 2011	Apr NEWA

DEXAMETHASONE SODIUM PHOSPHATE

	INJECTABLE; INJECTION						
	DEXAMETHASONE SODIUM PHOSPHATE						
>D>	AP AKORN STRIDES	EQ 4MG PHOSPHATE/ML		A040803	001	Aug 29, 2008	May CAHN
>D>	AP	EQ 10MG PHOSPHATE/ML		A040802	001	Aug 29, 2008	May CAHN
>A>	AP PFIZER	EQ 4MG PHOSPHATE/ML		A040803	001	Aug 29, 2008	May CAHN
>A>	AP	EQ 10MG PHOSPHATE/ML		A040802	001	Aug 29, 2008	May CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

	OINTMENT; OPHTHALMIC						
	NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE						
AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM		A062938	001	Jul 31, 1989	Feb CAHN
AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM		A062938	001	Jul 31, 1989	Jan CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL						
	FOCALIN XR						
>A>	NOVARTIS	25MG		N021802	008	Apr 21, 2011	May NEWA
>A>		35MG		N021802	007	Apr 21, 2011	May NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

	SYRUP; ORAL						
	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE						
AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML		A090575	001	Feb 08, 2011	Jan NEWA

DICLOFENAC SODIUM

TABLET, EXTENDED RELEASE; ORAL
DICLOFENAC SODIUM

AB	VALEANT INTL	100MG	A075492 001	Feb 11, 2000	Apr	CAHN
----	--------------	-------	-------------	--------------	-----	------

DIFLUPREDNATE

EMULSION; OPHTHALMIC
DUREZOL

>A>	+	ALCON PHARMS LTD	0.05%	N022212 001	Jun 23, 2008	May	CAHN
>D>	+	ALCON RES	0.05%	N022212 001	Jun 23, 2008	May	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

AB3	VALEANT INTL	120MG	A075116 001	Dec 23, 1999	Apr	CAHN
AB3		180MG	A075116 002	Dec 23, 1999	Apr	CAHN
AB3		240MG	A075116 003	Dec 23, 1999	Apr	CAHN
AB3		300MG	A075116 004	Dec 23, 1999	Apr	CAHN

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB		75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISULFIRAM

TABLET; ORAL
ANTABUSE

AB	ODYSSEY PHARMS	250MG	A088482 001	Dec 08, 1983	Mar	CTEC
AB	+	500MG	A088483 001	Dec 08, 1983	Mar	CTEC
DISULFIRAM						
AB	SIGMAPHARM LABS LLC	250MG	A091619 001	Mar 28, 2011	Mar	NEWA
AB		500MG	A091619 002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DIVALPROEX SODIUM

AB	MYLAN	EQ 125MG VALPROIC ACID	A090407 001	Mar 28, 2011	Mar	NEWA
----	-------	------------------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

AB	AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554 001	Apr 21, 2011	Apr	NEWA
AB		EQ 250MG VALPROIC ACID	A090554 002	Apr 21, 2011	Apr	NEWA
AB		EQ 500MG VALPROIC ACID	A090554 003	Apr 21, 2011	Apr	NEWA
AB	UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163 001	Apr 05, 2011	Mar	NEWA
AB		EQ 250MG VALPROIC ACID	A079163 002	Apr 05, 2011	Mar	NEWA
AB		EQ 500MG VALPROIC ACID	A079163 003	Apr 05, 2011	Mar	NEWA
AB	WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080 001	Feb 25, 2011	Feb	NEWA

DOCETAXEL

>A>	INJECTABLE; INJECTION						
>A>	DOCEFREZ						
>A>	+	SUN PHARMA GLOBAL	20MG/VIAL	N022534 001	May 03, 2011	May	NEWA
>A>	+		80MG/VIAL	N022534 002	May 03, 2011	May	NEWA

>A>	INJECTABLE; INJECTION							
	DOCETAXEL							
+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Mar	NEWA	
+		80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Mar	NEWA	
+		160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Mar	NEWA	
	TAXOTERE							
	@ SANOFI AVENTIS US	40MG/ML	N020449	001	May 14, 1996	Mar	DISC	

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	ACTAVIS PHARMA	5MG	A090551	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A090551	002	May 31, 2011	May	NEWA
>A>	AB	APOTEX	5MG	A078841	001	Jun 02, 2011	May	NEWA
>A>	AB		10MG	A078841	002	Jun 02, 2011	May	NEWA
>A>	AB	AUROBINDO	5MG	A090056	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A090056	002	May 31, 2011	May	NEWA
>A>	AB	CIPLA LTD	5MG	A077518	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A077518	002	May 31, 2011	May	NEWA
>A>	AB	DR REDDYS LABS LTD	5MG	A201001	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A201001	002	May 31, 2011	May	NEWA
>A>	AB	HIKMA PHARMS	5MG	A090247	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A090247	002	May 31, 2011	May	NEWA
>A>	AB	HUAHAI US INC	5MG	A200292	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A200292	002	May 31, 2011	May	NEWA
>A>	AB	JUBILANT LIFE	5MG	A090768	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A090768	002	May 31, 2011	May	NEWA
>A>	AB	MATRIX LABS LTD	5MG	A090521	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A090521	002	May 31, 2011	May	NEWA
>A>	AB	PLIVA HRVATSKA DOO	5MG	A090425	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A090425	002	May 31, 2011	May	NEWA
>A>	AB	ROXANE	5MG	A078662	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A078662	002	May 31, 2011	May	NEWA
>A>	AB	SANDOZ	5MG	A090290	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A090290	002	May 31, 2011	May	NEWA
>A>	AB	SUN PHARM INDS	5MG	A090493	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A090493	002	May 31, 2011	May	NEWA
>A>	AB	TEVA	5MG	A077344	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A077344	002	May 31, 2011	May	NEWA
>A>	AB	TORRENT PHARMS	5MG	A090686	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A090686	002	May 31, 2011	May	NEWA
>A>	AB	WOCKHARDT	5MG	A091267	001	May 31, 2011	May	NEWA
>A>	AB		10MG	A091267	002	May 31, 2011	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

AB	SANDOZ	5MG	A091198	001	May 10, 2011	Apr	NEWA
AB		10MG	A091198	002	May 10, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011	Apr	NEWA
AB		10MG	A090175	002	May 10, 2011	Apr	NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Jan	NEWA
AB	MYLAN	40MG	A090855	001	Jul 01, 2010	Jan	CDFR
AB	+ PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005	Feb	CTEC

CAPSULE; ORAL

DOXYCYCLINE

AB	+	PAR PHARM	EQ 150MG BASE	A065055 003	Jul 15, 2005	Jan	CTEC
----	---	-----------	---------------	-------------	--------------	-----	------

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

>D>	AB		WATSON LABS	EQ 50MG BASE	A062031 002	Oct 13, 1982	May	CAHN
>D>	AB			EQ 100MG BASE	A062031 001		May	CAHN
>A>	AB		WATSON LABS FLORIDA	EQ 50MG BASE	A062031 002	Oct 13, 1982	May	CAHN
>A>	AB			EQ 100MG BASE	A062031 001		May	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

LORYNA

AB		SANDOZ	3MG;0.02MG	A079221 001	Mar 28, 2011	Mar	NEWA
----	--	--------	------------	-------------	--------------	-----	------

TABLET; ORAL-28

SYEDA

AB		SANDOZ	3MG;0.03MG	A090114 001	Mar 28, 2011	Mar	NEWA
----	--	--------	------------	-------------	--------------	-----	------

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

LOVENOX

		SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164 009	Jan 23, 2003	Feb	CDFR
--	--	-------------------	----------------------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT	+	ALLERGAN	0.05%	N021565 001	Oct 16, 2003	Feb	CFTG
----	---	----------	-------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

AT		CYPRESS PHARM	0.05%	A090870 001	Mar 14, 2011	Feb	NEWA
----	--	---------------	-------	-------------	--------------	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266 001	Apr 15, 2011	Apr	NEWA
----	--	----------------	--------------------	-------------	--------------	-----	------

AP			200MG/100ML (2MG/ML)	A090266 002	Apr 15, 2011	Apr	NEWA
----	--	--	----------------------	-------------	--------------	-----	------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB		ARBOR PHARMS INC	250MG	A062746 001	Dec 22, 1986	Jan	CAHN
----	--	------------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

E-GLADES

AT		COREPHARMA	2%	A065009 001	Mar 18, 2002	Apr	CAHN
----	--	------------	----	-------------	--------------	-----	------

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT	+	FERA PHARMS	0.5%	A062447 001	Sep 26, 1983	Feb	CAHN
----	---	-------------	------	-------------	--------------	-----	------

AT	+	NYCOMED US	0.5%	A062447 001	Sep 26, 1983	Jan	CAHN
----	---	------------	------	-------------	--------------	-----	------

SOLUTION; TOPICAL

ERYDERM

		@ ARBOR PHARMS INC	2%	A062290 001		Jan	CAHN
--	--	--------------------	----	-------------	--	-----	------

ERYTHROMYCIN

		@ COREPHARMA	2%	A064127 001	Feb 14, 1997	Apr	CAHN
--	--	--------------	----	-------------	--------------	-----	------

SWAB; TOPICAL

ERYTHROMYCIN

@ COREPHARMA

2%

A064128 001 Jul 03, 1996 Apr CAHN

TABLET; ORAL

ERYTHROMYCIN

ARBOR PHARMS INC

250MG

A061621 001

Jan CAHN

+

500MG

A061621 002

Jan CAHN

TABLET, COATED PARTICLES; ORAL

PCE

ARBOR PHARMS INC

333MG

N050611 001 Sep 09, 1986 Jan CAHN

+

500MG

N050611 002 Aug 22, 1990 Jan CAHN

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

@ ARBOR PHARMS INC

250MG

A060272 001

Jan CAHN

@

333MG

A060272 002

Jan CAHN

ERY-TAB

+ ARBOR PHARMS INC

250MG

A062298 001

Jan CAHN

+

333MG

A062298 003 Mar 29, 1982 Jan CAHN

+

500MG

A062298 002

Jan CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB ARBOR PHARMS INC

EQ 200MG BASE/5ML

N050207 001

Jan CAHN

ERYPED

AB ARBOR PHARMS INC

EQ 200MG BASE/5ML

N050207 003 Mar 30, 1987 Jan CAHN

+

EQ 400MG BASE/5ML

N050207 002

Jan CAHN

SUSPENSION; ORAL

E.E.S. 200

AB ARBOR PHARMS INC

EQ 200MG BASE/5ML

A061639 001

Jan CAHN

E.E.S. 400

AB + ARBOR PHARMS INC

EQ 400MG BASE/5ML

A061639 002

Jan CAHN

PEDIAMYCIN

AB ARBOR PHARMS INC

EQ 200MG BASE/5ML

A062304 001

Jan CAHN

PEDIAMYCIN 400

AB ARBOR PHARMS INC

EQ 400MG BASE/5ML

A062304 002

Jan CAHN

TABLET; ORAL

E.E.S. 400

@ ARBOR PHARMS INC

EQ 400MG BASE

A061905 001

Jan CAHN

BX +

EQ 400MG BASE

A061905 002 Aug 12, 1982 Jan CAHN

ERYTHROMYCIN ETHYLSUCCINATE

BX + ARBOR PHARMS INC

EQ 400MG BASE

A061904 001

Jan CAHN

TABLET, CHEWABLE; ORAL

E.E.S.

@ ARBOR PHARMS INC

EQ 200MG BASE

N050297 002

Jan CAHN

ERYPED

@ ARBOR PHARMS INC

EQ 200MG BASE

N050297 003 Jul 05, 1988 Jan CAHN

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

@ ARBOR PHARMS INC

EQ 125MG BASE

A060359 002

Jan CAHN

EQ 250MG BASE

A060359 001

Jan CAHN

+

EQ 500MG BASE

A060359 003

Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

AB NOVO NORDISK INC 0.5MG;0.1MG N020907 002 Dec 28, 2006 Mar CTEC

ESTRADIOL AND NORETHINDRONE ACETATE

>A> AB BRECKENRIDGE PHARM 0.5MG;0.1MG A078324 002 Jun 09, 2011 May NEWA

ESTROPIPATE

CREAM; VAGINAL

OGEN

@ PHARMACIA AND UPJOHN 1.5MG/GM A084710 001 Apr DISC

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

>A> AB TEVA 1MG A091169 001 May 23, 2011 May NEWA

>A> AB 2MG A091169 002 May 23, 2011 May NEWA

>A> AB 3MG A091169 003 May 23, 2011 May NEWA

LUNESTA

>D> SEPRACOR 1MG N021476 001 Dec 15, 2004 May CFTG

>D> 2MG N021476 002 Dec 15, 2004 May CFTG

>D> + 3MG N021476 003 Dec 15, 2004 May CFTG

>A> AB SUNOVION PHARMS INC 1MG N021476 001 Dec 15, 2004 May CFTG

>A> AB 2MG N021476 002 Dec 15, 2004 May CFTG

>A> AB + 3MG N021476 003 Dec 15, 2004 May CFTG

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A> AB WATSON LABS 0.02MG;0.09MG A079218 001 Jun 06, 2011 May NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

>A> AB WATSON LABS 0.03MG,0.01MG;0.15MG,N/A A078834 001 May 31, 2011 May NEWA

LYBREL

>D> + WYETH PHARMS INC 0.02MG;0.09MG N021864 001 May 22, 2007 May CFTG

>A> AB + 0.02MG;0.09MG N021864 001 May 22, 2007 May CFTG

SEASONIQUE

>D> + DURAMED RES 0.03MG,0.01MG;0.15MG,N/A N021840 001 May 25, 2006 May CFTG

>A> AB + TEVA WOMENS 0.03MG,0.01MG;0.15MG,N/A N021840 001 May 25, 2006 May CFTG

TABLET; ORAL-28

ORSYTHIA

AB1 VINTAGE PHARMS 0.02MG;0.1MG A077099 001 May 11, 2011 Apr NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

BRIELLYN

AB GLENMARK GENERICS 0.035MG;0.4MG A090538 001 Mar 22, 2011 Mar NEWA

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

+ WARNER CHILCOTT 0.025MG;0.8MG N022573 001 Dec 22, 2010 Jan CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

LO LOESTRIN FE

>D> WARNER CHILCOTT CO 0.01MG,0.01MG;1MG,N/A N022501 001 Oct 21, 2010 May CRLD

>A> + 0.01MG,0.01MG;1MG,N/A N022501 001 Oct 21, 2010 May CRLD

TABLET; ORAL-28

		GILDESS FE 1.5/30							
AB		VINTAGE	0.03MG;1.5MG	A077075	001	Apr 28, 2005	Jan	CTNA	
		GILDESS FE 1/20							
AB		VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005	Jan	CTNA	

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

		NORGESTIMATE AND ETHINYL ESTRADIOL							
AB		WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011	Feb	NEWA	

ETHOSUXIMIDE

CAPSULE; ORAL

		ETHOSUXIMIDE							
>D>	AB	COVENANT PHARMA INC	250MG	A040686	001	May 28, 2008	May	CAHN	
>A>	AB	VERSAPHARM	250MG	A040686	001	May 28, 2008	May	CAHN	

ETODOLAC

CAPSULE; ORAL

ETODOLAC

@ MYLAN

200MG

A075071 001 Sep 30, 1998 Feb CAHN

@

300MG

A075071 002 Sep 30, 1998 Feb CAHN

TABLET; ORAL

ETODOLAC

@ MYLAN

400MG

A075012 001 Sep 30, 1998 Feb CAHN

@

500MG

A075012 002 Sep 30, 1998 Feb CAHN

ETONOGESTREL

IMPLANT; IMPLANTATION

		NEXPLANON							
>A>									
>A>	+	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011	May	NEWA	

ETRAVIRINE

TABLET; ORAL

INTELENCE

TIBOTEC

100MG

N022187 001 Jan 18, 2008 Jan CRLD

+

200MG

N022187 002 Dec 22, 2010 Jan NEWA

EXEMESTANE

TABLET; ORAL

AROMASIN

AB	+	PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999	Mar	CFTG	
----	---	----------------------	------	---------	-----	--------------	-----	------	--

EXEMESTANE

AB		ROXANE	25MG	A077431	001	Apr 01, 2011	Mar	NEWA	
----	--	--------	------	---------	-----	--------------	-----	------	--

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB		AUROBINDO PHARMA LTD	125MG	A091114	001	Mar 21, 2011	Mar	NEWA	
AB			250MG	A091114	002	Mar 21, 2011	Mar	NEWA	
AB			500MG	A091114	003	Mar 21, 2011	Mar	NEWA	
AB		MYLAN	125MG	A201333	001	Mar 24, 2011	Mar	NEWA	
AB			250MG	A201333	002	Mar 24, 2011	Mar	NEWA	
AB			500MG	A201333	003	Mar 24, 2011	Mar	NEWA	
AB		ROXANE	125MG	A090128	001	Mar 21, 2011	Mar	NEWA	

TABLET; ORAL

FAMCICLOVIR

AB	ROXANE	250MG	A090128 002	Mar 21, 2011	Mar	NEWA
AB		500MG	A090128 003	Mar 21, 2011	Mar	NEWA
AB	WATSON LABS	125MG	A078278 001	Mar 21, 2011	Mar	NEWA
AB		250MG	A078278 002	Mar 21, 2011	Mar	NEWA
AB		500MG	A078278 003	Mar 21, 2011	Mar	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

>D>	AP	AKORN STRIDES	10MG/ML	A078641 001	Jun 25, 2008	May	CAHN
>A>	AP	PFIZER	10MG/ML	A078641 001	Jun 25, 2008	May	CAHN

FAMOTIDINE PRESERVATIVE FREE

>D>	AP	AKORN STRIDES	10MG/ML	A078642 001	Jun 25, 2008	May	CAHN
>A>	AP	PFIZER	10MG/ML	A078642 001	Jun 25, 2008	May	CAHN

PEPCID

@	MERCK	10MG/ML	N019510 001	Nov 04, 1986	Jan	DISC
---	-------	---------	-------------	--------------	-----	------

PEPCID PRESERVATIVE FREE

@	MERCK	10MG/ML	N019510 004	Nov 04, 1986	Jan	DISC
---	-------	---------	-------------	--------------	-----	------

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

@	MERCK	0.4MG/ML	N020249 001	Feb 18, 1994	Jan	DISC
---	-------	----------	-------------	--------------	-----	------

TABLET; ORAL

FAMOTIDINE

AB	MYLAN	20MG	A075457 001	Apr 18, 2001	Feb	CAHN
AB		40MG	A075457 002	Apr 18, 2001	Feb	CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+	HORIZON PHARMA	26.6MG;800MG	N022519 001	Apr 23, 2011	Apr	NEWA
---	----------------	--------------	-------------	--------------	-----	------

FENOFIBRATE

TABLET; ORAL

FENOGLIDE

	SHORE THERAP	40MG	N022118 001	Aug 10, 2007	Feb	CAHN
+		120MG	N022118 002	Aug 10, 2007	Feb	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB	MALLINCKRODT INC	100MCG/HR	A077154 004	Feb 09, 2011	Jan	NEWA
----	------------------	-----------	-------------	--------------	-----	------

FENTANYL-25

AB	MALLINCKRODT INC	25MCG/HR	A077154 001	Feb 09, 2011	Jan	NEWA
----	------------------	----------	-------------	--------------	-----	------

FENTANYL-50

AB	MALLINCKRODT INC	50MCG/HR	A077154 002	Feb 09, 2011	Jan	NEWA
----	------------------	----------	-------------	--------------	-----	------

FENTANYL-75

AB	MALLINCKRODT INC	75MCG/HR	A077154 003	Feb 09, 2011	Jan	NEWA
----	------------------	----------	-------------	--------------	-----	------

FENTANYL CITRATE

TABLET; SUBLINGUAL

ABSTRAL

	PROSTRAKAN INC	EQ 0.1MG BASE	N022510 001	Jan 07, 2011	Jan	NEWA
		EQ 0.2MG BASE	N022510 002	Jan 07, 2011	Jan	NEWA
		EQ 0.3MG BASE	N022510 003	Jan 07, 2011	Jan	NEWA
+		EQ 0.4MG BASE	N022510 004	Jan 07, 2011	Jan	NEWA

TABLET; SUBLINGUAL

ABSTRAL

PROSTRAKAN INC	EQ 0.6MG BASE	N022510 005	Jan 07, 2011	Jan	NEWA
	EQ 0.8MG BASE	N022510 006	Jan 07, 2011	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD	180MG;240MG	A079043 001	Mar 17, 2010	Jan	CTEC
--------------------	-------------	-------------	--------------	-----	------

>A> FIDAXOMICIN

>A> TABLET; ORAL

>A> DIFICID

>A> + OPTIMER PHARMS	200MG	N201699 001	May 27, 2011	May	NEWA
----------------------	-------	-------------	--------------	-----	------

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB	AMNEAL PHARM	50MG	A078423 001	Mar 07, 2011	Feb	NEWA
AB		100MG	A078423 002	Mar 07, 2011	Feb	NEWA
AB		150MG	A078423 003	Mar 07, 2011	Feb	NEWA
AB		200MG	A078423 004	Mar 07, 2011	Feb	NEWA
AB	MYLAN	50MG	A076042 001	Jul 29, 2004	Feb	CAHN
AB		100MG	A076042 002	Jul 29, 2004	Feb	CAHN
AB		150MG	A076042 003	Jul 29, 2004	Feb	CAHN
AB		200MG	A076042 004	Jul 29, 2004	Feb	CAHN

FLUDARABINE PHOSPHATE

TABLET; ORAL

OFORTA

+ SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008	Apr	CMFD
@	10MG	N022273 001	Dec 18, 2008	Jan	DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP + FEINSTEIN	20-200mCi/ML	N021870 001	Aug 19, 2005	Feb	CTEC
AP PETNET	20-200mCi/ML	A079086 001	Feb 25, 2011	Feb	NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

>D> AP	AKORN STRIDES	0.5MG/5ML (0.1MG/ML)	A078595 001	May 13, 2008	May	CAHN
>D> AP		1MG/10ML (0.1MG/ML)	A078595 002	May 13, 2008	May	CAHN
>A> AP	PFIZER	0.5MG/5ML (0.1MG/ML)	A078595 001	May 13, 2008	May	CAHN
>A> AP		1MG/10ML (0.1MG/ML)	A078595 002	May 13, 2008	May	CAHN

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	SANDOZ	5GM/100ML (50MG/ML)	A091299 002	May 02, 2011	Apr	NEWA
AP		2.5GM/50ML (50MG/ML)	A091299 001	May 02, 2011	Apr	NEWA
	@ VALEANT	500MG/10ML (50MG/ML)	N012209 001		Mar	DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223 001	Mar 19, 2009	Apr	CAHN
AB1		EQ 20MG BASE	A090223 002	Mar 19, 2009	Apr	CAHN
AB		EQ 40MG BASE	A090223 003	Mar 19, 2009	Apr	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	MYLAN	125MG	A076224 001	May 09, 2003	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

LOTION; TOPICAL

CUTIVATE

AB	+	NYCOMED US	0.05%	N021152 001	Mar 31, 2005	Apr	CFTG
----	---	------------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

AB		GLENMARK GENERICS	0.05%	A090759 001	May 02, 2011	Apr	NEWA
----	--	-------------------	-------	-------------	--------------	-----	------

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ MYLAN

50MG

A075950 001	Oct 15, 2001	Feb	CAHN
-------------	--------------	-----	------

@

100MG

A075950 002	Oct 15, 2001	Feb	CAHN
-------------	--------------	-----	------

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	+	AMNEAL PHARM	1MG	A040625 001	Jul 21, 2005	Apr	CAHN
----	---	--------------	-----	-------------	--------------	-----	------

AA		JUBILANT CADISTA	1MG	A040514 001	Jun 14, 2005	Jan	CAHN
----	--	------------------	-----	-------------	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB	AUROBINDO PHARMA LTD	10MG	A091163 001	Mar 30, 2011	Mar	NEWA
----	----------------------	------	-------------	--------------	-----	------

AB		20MG	A091163 002	Mar 30, 2011	Mar	NEWA
----	--	------	-------------	--------------	-----	------

AB		40MG	A091163 003	Mar 30, 2011	Mar	NEWA
----	--	------	-------------	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

>D>	AP	AKORN STRIDES	EQ 50MG PNEYTOIN NA/ML	A078476 001	Mar 18, 2008	May	CAHN
-----	----	---------------	------------------------	-------------	--------------	-----	------

AP	+	APP PHARMS	EQ 50MG PHENYTOIN NA/ML	A078052 001	Aug 06, 2007	Apr	CRLD
----	---	------------	-------------------------	-------------	--------------	-----	------

>A>	AP	PFIZER	EQ 50MG PNEYTOIN NA/ML	A078476 001	Mar 18, 2008	May	CAHN
-----	----	--------	------------------------	-------------	--------------	-----	------

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

>D>	AB	MATRIX LABS LTD	100MG	A090158 001	Feb 14, 2011	May	CAHN
-----	----	-----------------	-------	-------------	--------------	-----	------

AB		100MG	A090158 001	Feb 14, 2011	Jan	NEWA
----	--	-------	-------------	--------------	-----	------

>D>	AB		300MG	A090158 002	Feb 14, 2011	May	CAHN
-----	----	--	-------	-------------	--------------	-----	------

AB		300MG	A090158 002	Feb 14, 2011	Jan	NEWA
----	--	-------	-------------	--------------	-----	------

>D>	AB		400MG	A090158 003	Feb 14, 2011	May	CAHN
-----	----	--	-------	-------------	--------------	-----	------

AB		400MG	A090158 003	Feb 14, 2011	Jan	NEWA
----	--	-------	-------------	--------------	-----	------

>A>	AB	MYLAN	100MG	A090158 001	Feb 14, 2011	May	CAHN
-----	----	-------	-------	-------------	--------------	-----	------

CAPSULE; ORAL

GABAPENTIN

>A>	AB	MYLAN	300MG	A090158 002	Feb 14, 2011	May	CAHN
>A>	AB		400MG	A090158 003	Feb 14, 2011	May	CAHN

SOLUTION; ORAL

GABAPENTIN

AA		HI TECH PHARMA	250MG/5ML	A078974 001	Feb 18, 2011	Feb	NEWA
AA	+	PARKE DAVIS	250MG/5ML	N021129 001	Mar 02, 2000	Feb	CFTG

TABLET; ORAL

GABAPENTIN

AB		ZYDUS PHARMS USA INC	600MG	A078926 001	Feb 11, 2011	Jan	NEWA
AB			800MG	A078926 002	Feb 11, 2011	Jan	NEWA
BX	+	ABBOTT PRODS	300MG	N022544 001	Jan 28, 2011	Jan	NEWA
BX	+		600MG	N022544 002	Jan 28, 2011	Jan	NEWA

GRALISE

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

	+	GLAXO GRP LTD	600MG	N022399 001	Apr 06, 2011	Apr	NEWA
--	---	---------------	-------	-------------	--------------	-----	------

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

	+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277 001	Mar 14, 2011	Mar	NEWA
	+		6.0472GM/10ML (604.72MG/ML)	N201277 002	Mar 14, 2011	Mar	NEWA
	+		9.0708GM/15ML (604.72MG/ML)	N201277 003	Mar 14, 2011	Mar	NEWA
	+		18.1416GM/30ML (604.72MG/ML)	N201277 004	Mar 14, 2011	Mar	NEWA
	+		39.3068GM/65ML (604.72MG/ML)	N201277 005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB		MYLAN	EQ 8MG BASE	A090900 001	Jan 24, 2011	Jan	NEWA
AB			EQ 16MG BASE	A090900 002	Jan 24, 2011	Jan	NEWA
AB			EQ 24MG BASE	A090900 003	Jan 24, 2011	Jan	NEWA
AB		SUN PHARMA GLOBAL	EQ 8MG BASE	A090178 001	Feb 02, 2011	Jan	NEWA
AB			EQ 16MG BASE	A090178 002	Feb 02, 2011	Jan	NEWA
AB			EQ 24MG BASE	A090178 003	Feb 02, 2011	Jan	NEWA

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957 001	Mar 29, 2011	Mar	NEWA
AB			EQ 8MG BASE	A090957 002	Mar 29, 2011	Mar	NEWA
AB			EQ 12MG BASE	A090957 003	Mar 29, 2011	Mar	NEWA
AB		ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898 001	Feb 17, 2011	Jan	NEWA
AB			EQ 8MG BASE	A078898 002	Feb 17, 2011	Jan	NEWA
AB			EQ 12MG BASE	A078898 003	Feb 17, 2011	Jan	NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE

>D>							
>D>	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	May	CTNA
	+		EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	Feb	CRLD
>A>	AP	APP PHARMS	EQ 2GM BASE/VIAL	A090242 003	May 16, 2011	May	NEWA

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

>A>	AP	FRESENIUS KABI ONCOL	EQ 2GM BASE/VIAL	A090799 003	May 16, 2011	May	NEWA
>A>	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	May	CTNA
	AP	TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983 002	Jan 25, 2011	Jan	NEWA
	AP		EQ 1GM BASE/VIAL	A077983 001	Jan 25, 2011	Jan	NEWA
		GEMZAR					
	AP	+ LILLY	EQ 200MG BASE/VIAL	N020509 001	May 15, 1996	Jan	CFTG
	AP	+	EQ 1GM BASE/VIAL	N020509 002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

	AB	BLU CARIBE	600MG	A078012 001	Mar 26, 2007	Feb	CAHN
--	----	------------	-------	-------------	--------------	-----	------

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

	AT	FERA PHARMS	EQ 0.3% BASE	A065024 001	Jul 30, 2004	Feb	CAHN
	AT	NYCOMED US	EQ 0.3% BASE	A065024 001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

	AT	FERA PHARMS	EQ 0.3% BASE	A065121 001	Jan 30, 2004	Feb	CAHN
--	----	-------------	--------------	-------------	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

	AB	MYLAN	1MG	A077486 001	Feb 10, 2006	Feb	CAHN
	AB		2MG	A077486 002	Feb 10, 2006	Feb	CAHN
	AB		4MG	A077486 003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

	AB	ZYDUS PHARMS USA INC	2.5MG;250MG	A078905 001	Jan 31, 2011	Jan	NEWA
	AB		2.5MG;500MG	A078905 002	Jan 31, 2011	Jan	NEWA
	AB		5MG;500MG	A078905 003	Jan 31, 2011	Jan	NEWA

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

>A>	+	EMMAUS MEDCL	5GM/PACKET	N021667 001	Jun 10, 2004	May	CAHN
>D>	+	NUTRITIONAL RESTART	5GM/PACKET	N021667 001	Jun 10, 2004	May	CAHN

GLYBURIDE

TABLET; ORAL

GLYBURIDE

>A>	AB	HERITAGE PHARMS INC	1.25MG	A090937 001	Feb 28, 2011	May	CAHN
>A>	AB		2.5MG	A090937 002	Feb 28, 2011	May	CAHN
>A>	AB		5MG	A090937 003	Feb 28, 2011	May	CAHN
>D>	AB	INDICUS PHARMA	1.25MG	A090937 001	Feb 28, 2011	May	CAHN
	AB		1.25MG	A090937 001	Feb 28, 2011	Feb	NEWA
>D>	AB		2.5MG	A090937 002	Feb 28, 2011	May	CAHN
	AB		2.5MG	A090937 002	Feb 28, 2011	Feb	NEWA
>D>	AB		5MG	A090937 003	Feb 28, 2011	May	CAHN
	AB		5MG	A090937 003	Feb 28, 2011	Feb	NEWA

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@ ELORAC 125MG A061996 001 Jan CAHN

@ 250MG A061996 002 Jan CAHN

FULVICIN P/G 165

@ ELORAC 165MG A061996 003 Apr 06, 1982 Jan CAHN

FULVICIN P/G 330

@ ELORAC 330MG A061996 004 Apr 06, 1982 Jan CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

>D> AP AKORN STRIDES EQ 5MG BASE/ML A078347 001 Sep 14, 2009 May CAHN

>A> AP PFIZER EQ 5MG BASE/ML A078347 001 Sep 14, 2009 May CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

>A> AP SANDOZ 1,000 UNITS/ML A091682 001 Jun 08, 2011 May NEWA

>A> AP 5,000 UNITS/ML A091682 002 Jun 08, 2011 May NEWA

>A> AP 5,000 UNITS/ML A091659 001 Jun 08, 2011 May NEWA

>A> AP 10,000 UNITS/ML A201002 001 Jun 08, 2011 May NEWA

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

>A> + GE HEALTHCARE 100MG/VIAL N022555 001 May 28, 2010 May CAHN

>D> + PHOTOCURE ASA 100MG/VIAL N022555 001 May 28, 2010 May CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AB NOVEL LABS INC 1.5MG;5MG A091528 001 Apr 20, 2011 Apr NEWA

TUSSIGON

AB + KING PHARMS 1.5MG;5MG A088508 001 Jul 30, 1985 Apr CTEC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB ALEMBIC PHARMS LTD 12.5MG A200645 001 Nov 30, 2010 Apr CAHN

AB JUBILANT CADISTA 12.5MG A078391 001 Feb 11, 2008 Jan CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB JUBILANT CADISTA 25MG A040809 001 Sep 04, 2007 Jan CAHN

AB 50MG A040809 002 Sep 04, 2007 Jan CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

>D> AB HUAHAI US INC 12.5MG;10MG A076230 001 Jul 01, 2002 May CAHN

>D> AB 12.5MG;20MG A076230 002 Jul 01, 2002 May CAHN

>D> AB 25MG;20MG A076230 003 Jul 01, 2002 May CAHN

>A> AB PRINSTON PHARM LLC 12.5MG;10MG A076230 001 Jul 01, 2002 May CAHN

>A> AB 12.5MG;20MG A076230 002 Jul 01, 2002 May CAHN

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

>A>	AB	PRINSTON PHARM LLC	25MG;20MG	A076230	003	Jul 01, 2002	May	CAHN
-----	----	--------------------	-----------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011	Jan	NEWA
AB		12.5MG;100MG	A200180	002	Jan 12, 2011	Jan	NEWA
AB		25MG;100MG	A200180	003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A201356	001	Apr 20, 2011	Apr	NEWA
AB		12.5MG;20MG	A201356	002	Apr 20, 2011	Apr	NEWA
AB		25MG;20MG	A201356	003	Apr 20, 2011	Apr	NEWA

HYDROCORTISONE

SOLUTION; TOPICAL

TEXACORT

>D>	+	JSJ PHARMS	2.5%	A081271	001	Apr 17, 1992	May	CAHN
>A>	+	TIBER LABS	2.5%	A081271	001	Apr 17, 1992	May	CAHN

TABLET; ORAL

HYDROCORTISONE

AB	COREPHARMA	5MG	A040646	001	Mar 30, 2007	Apr	CAHN
AB		10MG	A040646	002	Mar 30, 2007	Apr	CAHN
AB		20MG	A040646	003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

@	FERA PHARMS	0.5%	A080828	001		Mar	CAHN
---	-------------	------	---------	-----	--	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

HYDROFLUMETHIAZIDE

>D>	AB	PAR PHARM	50MG	A088850	001	May 31, 1985	May	DISC
>A>	@		50MG	A088850	001	May 31, 1985	May	DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	ELITE LABS	8MG	A076723	001	Oct 18, 2005	Feb	CAHN
----	------------	-----	---------	-----	--------------	-----	------

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

@	MERCK SANTE SAS	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	DISC
---	-----------------	--------------------	---------	-----	--------------	-----	------

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRINE

@	PHARMICS	1%	N000004	004		Jan	CAHN
---	----------	----	---------	-----	--	-----	------

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+	KV PHARM	1250MG/5ML (250MG/ML)	N021945 001	Feb 03, 2011	Feb	NEWA
---	----------	-----------------------	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP	SANDOZ	1MG/ML	A091293 001	Mar 29, 2011	Mar	NEWA
----	--------	--------	-------------	--------------	-----	------

ILOPERIDONE

TABLET; ORAL

FANAPT

NOVARTIS

2MG

N022192 002	May 06, 2009	Jan	CAHN
-------------	--------------	-----	------

4MG

N022192 003	May 06, 2009	Jan	CAHN
-------------	--------------	-----	------

6MG

N022192 004	May 06, 2009	Jan	CAHN
-------------	--------------	-----	------

8MG

N022192 005	May 06, 2009	Jan	CAHN
-------------	--------------	-----	------

10MG

N022192 006	May 06, 2009	Jan	CAHN
-------------	--------------	-----	------

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	TARO	5%	A200173 001	Apr 15, 2011	Apr	NEWA
----	------	----	-------------	--------------	-----	------

AB	TEVA PHARMS USA	5%	A200481 001	Apr 18, 2011	Apr	NEWA
----	-----------------	----	-------------	--------------	-----	------

AB	TOLMAR	5%	A091044 001	Feb 28, 2011	Feb	NEWA
----	--------	----	-------------	--------------	-----	------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB	HETERO DRUGS LTD	25MG	A091240 001	Apr 12, 2011	Mar	NEWA
----	------------------	------	-------------	--------------	-----	------

AB		50MG	A091240 002	Apr 12, 2011	Mar	NEWA
----	--	------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	+	SANDOZ	75MG	A074464 001	May 28, 1998	Jan	CTNA
----	---	--------	------	-------------	--------------	-----	------

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+	GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454 001	Jan 14, 2011	Jan	NEWA
---	-----------------	----------------------	-------------	--------------	-----	------

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

@ HOSPIRA

41%

A074898 001	Dec 30, 1997	Feb	DISC
-------------	--------------	-----	------

IOPAMIDOL-200 IN PLASTIC CONTAINER

@ HOSPIRA

41%

A074636 001	Dec 30, 1997	Feb	DISC
-------------	--------------	-----	------

IOPAMIDOL-250

@ HOSPIRA

51%

A074898 002	Dec 30, 1997	Feb	DISC
-------------	--------------	-----	------

IOPAMIDOL-250 IN PLASTIC CONTAINER

@ HOSPIRA

51%

A074636 002	Dec 30, 1997	Feb	DISC
-------------	--------------	-----	------

IOPAMIDOL-300

@ HOSPIRA

61%

A074898 003	Dec 30, 1997	Feb	DISC
-------------	--------------	-----	------

IOPAMIDOL-300 IN PLASTIC CONTAINER

@ HOSPIRA

61%

A074636 003	Dec 30, 1997	Feb	DISC
-------------	--------------	-----	------

INJECTABLE; INJECTION

IOPAMIDOL-370

@ HOSPIRA 76% A074898 004 Dec 30, 1997 Feb DISC

IOPAMIDOL-370 IN PLASTIC CONTAINER

@ HOSPIRA 76% A074636 004 Dec 30, 1997 Feb DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

>A> AP BIONICHE PHARMA 40MG/2ML (20MG/ML) A090393 002 May 13, 2011 May NEWA

>A> AP 100MG/5ML (20MG/ML) A090393 003 May 13, 2011 May NEWA

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD EQ 50MG BASE/2.5ML (EQ 20MG
BASE/ML) N021135 002 Mar 20, 2005 Apr CMFDISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

>A> AB TORRENT PHARMS 30MG A200270 001 Jun 03, 2011 May NEWA

>A> AB 60MG A200495 001 Jun 03, 2011 May NEWA

>A> AB 120MG A200495 002 Jun 03, 2011 May NEWA

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB MIKAH PHARMA 2.5MG A077169 001 Apr 24, 2006 Feb CAHN

AB 5MG A077169 002 Apr 24, 2006 Feb CAHN

ITRACONAZOLE

INJECTABLE; INJECTION

SPORANOX

>D> + ORTHO MCNEIL JANSSEN 10MG/ML N020966 001 Mar 30, 1999 May DISC

>A> @ 10MG/ML N020966 001 Mar 30, 1999 May DISC

TABLET; ORAL

ITRACONAZOLE

>D> + STIEFEL LABS INC 200MG N022484 001 Apr 29, 2010 May CTNA

>A> ONMEL

>A> + STIEFEL LABS INC 200MG N022484 001 Apr 29, 2010 May CTNA

KETOCONAZOLE

GEL; TOPICAL

XOLEGEL

>A> + AQUA PHARMS 2% N021946 001 Jul 28, 2006 May CAHN

>D> + STIEFEL LABS INC 2% N021946 001 Jul 28, 2006 May CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>D> AP AKORN STRIDES 15MG/ML A078299 001 Jul 16, 2007 May CAHN

>D> AP 30MG/ML A078299 002 Jul 16, 2007 May CAHN

>A> AP PFIZER 15MG/ML A078299 001 Jul 16, 2007 May CAHN

>A> AP 30MG/ML A078299 002 Jul 16, 2007 May CAHN

SPRAY, METERED; NASAL

SPRIX

>A>	+	LUITPOLD	15.75MG/SPRAY	N022382	001	May 14, 2010	May	CAHN
>D>	+	ROXRO PHARMA INC	15.75MG/SPRAY	N022382	001	May 14, 2010	May	CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

>D>	+	VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	May	CFTG
>A>	AB	+	150MG;300MG	N020857	001	Sep 26, 1997	May	CFTG
>A>		LAMIVUDINE AND ZIDOVUDINE						
>A>	AB	TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011	May	NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB		ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	Mar	NEWA
AB			100MG	A078669	002	Apr 08, 2011	Mar	NEWA
AB			150MG	A078669	003	Apr 08, 2011	Mar	NEWA
AB			200MG	A078669	004	Apr 08, 2011	Mar	NEWA
AB		ALEMBIC LTD	25MG	A090607	001	Jan 13, 2011	Jan	NEWA
AB			100MG	A090607	002	Jan 13, 2011	Jan	NEWA
AB			150MG	A090607	003	Jan 13, 2011	Jan	NEWA
AB			200MG	A090607	004	Jan 13, 2011	Jan	NEWA
AB		ALEMBIC PHARMS LTD	25MG	A090607	001	Jan 13, 2011	Apr	CAHN
AB			100MG	A090607	002	Jan 13, 2011	Apr	CAHN
AB			150MG	A090607	003	Jan 13, 2011	Apr	CAHN
AB			200MG	A090607	004	Jan 13, 2011	Apr	CAHN
AB		HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	Apr	NEWA
AB			100MG	A078134	002	Apr 19, 2011	Apr	NEWA
AB			150MG	A078134	003	Apr 19, 2011	Apr	NEWA
AB			200MG	A078134	004	Apr 19, 2011	Apr	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB		JUBILANT LIFE	5MG	A200220	001	Feb 28, 2011	Feb	NEWA
AB			25MG	A200220	002	Feb 28, 2011	Feb	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT		ALCON RES	0.005%	A091449	001	Mar 22, 2011	Mar	NEWA
AT		APOTEX	0.005%	A077697	001	Mar 22, 2011	Mar	NEWA
AT		BAUSCH AND LOMB	0.005%	A201006	001	Mar 22, 2011	Mar	NEWA
>A>	AT	LUITPOLD	0.005%	A200925	001	Mar 22, 2011	May	CAHN
AT		MYLAN	0.005%	A201786	001	Mar 22, 2011	Mar	NEWA
>D>	AT	PHARMAFORCE	0.005%	A200925	001	Mar 22, 2011	May	CAHN
AT			0.005%	A200925	001	Mar 22, 2011	Mar	NEWA
		XALATAN						
AT	+	PHARMACIA AND UPJOHN	0.005%	N020597	001	Jun 05, 1996	Mar	CFTG

LETROZOLE

TABLET; ORAL

LETROZOLE

>A>	AB	ACCORD HLTHCARE	2.5MG	A090934	001	Jun 03, 2011	May	NEWA
>A>	AB	DR REDDYS LABS LTD	2.5MG	A091191	001	Jun 03, 2011	May	NEWA
>A>	AB	ENDO PHARMS	2.5MG	A090789	001	Jun 03, 2011	May	NEWA

TABLET; ORAL

LETROZOLE

>A>	AB	FRESENIUS KABI ONCOL	2.5MG	A090491	001	Jun 03, 2011	May	NEWA
>A>	AB	IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011	May	NEWA
>A>	AB	INDICUS PHARMA	2.5MG	A201804	001	Jun 03, 2011	May	NEWA
>A>	AB	KUDCO IRELAND	2.5MG	A091098	001	Jun 03, 2011	May	NEWA
>A>	AB	NATCO PHARMA LTD	2.5MG	A200161	001	Jun 03, 2011	May	NEWA
>A>	AB	ROXANE	2.5MG	A090838	001	Jun 03, 2011	May	NEWA
>A>	AB	SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011	May	NEWA
>A>	AB	SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011	May	NEWA
>A>	AB	TEVA PHARMS	2.5MG	A090289	001	Jun 03, 2011	May	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

@ GENZYME

1MG/0.2ML

A075721 001 Nov 29, 2001 Apr DISC

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

AB		ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	Jan	NEWA
AB			500MG	A090843	002	Feb 14, 2011	Jan	NEWA
AB			750MG	A090843	003	Feb 14, 2011	Jan	NEWA
AB			1GM	A090843	004	Feb 14, 2011	Jan	NEWA
>A>	AB	AJANTA PHARMA	250MG	A201293	001	Jun 14, 2011	May	NEWA
>A>	AB		500MG	A201293	002	Jun 14, 2011	May	NEWA
>A>	AB		750MG	A201293	003	Jun 14, 2011	May	NEWA
>A>	AB		1GM	A201293	004	Jun 14, 2011	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		DR REDDYS LABS LTD	5MG	A090392	001	Feb 24, 2011	Feb	NEWA
AB		GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Feb	NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT		HI TECH PHARMA	0.5%	A076826	001	Feb 10, 2011	Jan	NEWA
----	--	----------------	------	---------	-----	--------------	-----	------

LEVOLEUCOVORIN CALCIUM

>D>		POWDER; IV (INFUSION)						
>D>		FUSILEV						
>D>	+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	May	CDFR
			EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	Apr	NEWA
>D>	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	May	CDFR
			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	Apr	NEWA
>A>		SOLUTION; IV (INFUSION)						
>A>		FUSILEV						
>A>	+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	May	CDFR
>A>	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	May	CDFR

LEVONORGESTREL

TABLET; ORAL

PLAN B

	@ TEVA WOMENS	0.75MG	N021045 001	Jul 28, 1999	Feb	CAHN
AB +		0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ VALEANT PHARM INTL

2MG

N008720 001 Dec 19, 1991 Mar DISC

LEVORPHANOL TARTRATE

ROXANE

2MG

A074278 001 Mar 31, 2000 Mar CTEC

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVO-T

AB1, AB2, AB3	ALARA PHARM	0.025MG	N021342 001	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.05MG	N021342 002	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.075MG	N021342 003	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.088MG	N021342 004	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.1MG	N021342 005	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.112MG	N021342 006	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.125MG	N021342 007	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.137MG	N021342 012	Dec 08, 2003	Feb	CTEC
AB1, AB2, AB3		0.15MG	N021342 008	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.175MG	N021342 009	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.2MG	N021342 010	Mar 01, 2002	Feb	CTEC
AB1, + AB2, AB3		0.3MG	N021342 011	Mar 01, 2002	Feb	CTEC

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

>A>	AT	NOVOCOL INC	5%	A040911 001	May 23, 2011	May	NEWA
-----	----	-------------	----	-------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT		HI TECH PHARMA	2%	A040837 001	Mar 23, 2011	Mar	NEWA
----	--	----------------	----	-------------	--------------	-----	------

>A> LINAGLIPTIN

>A> TABLET; ORAL

>A> TRADJENTA

>A> + BOEHRINGER INGELHEIM 5MG N201280 001 May 02, 2011 May NEWA

LISINAPRIL

TABLET; ORAL

LISINAPRIL

>D> AB HUAHAI US INC 2.5MG A076180 001 Jul 01, 2002 May CAHN

>D> AB 5MG A076180 002 Jul 01, 2002 May CAHN

>D> AB 10MG A076180 003 Jul 01, 2002 May CAHN

>D> AB 20MG A076164 001 Jul 01, 2002 May CAHN

>D> AB 30MG A076164 002 Jul 01, 2002 May CAHN

>D> AB 40MG A076164 003 Jul 01, 2002 May CAHN

>A> AB PRINSTON PHARM LLC 2.5MG A076180 001 Jul 01, 2002 May CAHN

>A> AB 5MG A076180 002 Jul 01, 2002 May CAHN

>A> AB 10MG A076180 003 Jul 01, 2002 May CAHN

>A> AB 20MG A076164 001 Jul 01, 2002 May CAHN

>A> AB 30MG A076164 002 Jul 01, 2002 May CAHN

>A> AB 40MG A076164 003 Jul 01, 2002 May CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB GLENMARK GENERICS 450MG A091616 001 Feb 14, 2011 Jan NEWA

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB ALEMBIC PHARMS LTD 25MG A090428 001 Oct 06, 2010 Apr CAHN

AB 50MG A090428 002 Oct 06, 2010 Apr NEWA

AB 100MG A090428 003 Oct 06, 2010 Apr CAHN

>A> AB HUAHAI US INC 25MG A091497 001 Jun 06, 2011 May NEWA

>A> AB 50MG A091497 002 Jun 06, 2011 May NEWA

>A> AB 100MG A091497 003 Jun 06, 2011 May NEWA

AB MYLAN 25MG A091590 001 Oct 06, 2010 Jan NEWA

AB 50MG A091590 002 Oct 06, 2010 Jan NEWA

AB 100MG A091590 003 Oct 06, 2010 Jan NEWA

LOTEPREDNOL ETABONATE

OINTMENT; OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB 0.5% N200738 001 Apr 15, 2011 Apr NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA AMNEAL PHARMS 12.5MG A201451 001 Feb 23, 2011 Feb NEWA

AA 25MG A201451 002 Feb 23, 2011 Feb NEWA

AA 50MG A201451 003 Feb 23, 2011 Feb NEWA

AA JUBILANT CADISTA 12.5MG A040659 001 Jun 04, 2010 Jan CAHN

AA 25MG A040659 002 Jun 04, 2010 Jan CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	MYLAN	7.5MG	A077934 001	Jul 20, 2006	Feb	CAHN
AB		15MG	A077934 002	Jul 20, 2006	Feb	CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE

>D>	@ SUN PHARM INDS (IN)	5MG	A090058 001	May 05, 2010	May	CAHN
>D>	@	10MG	A090058 002	May 05, 2010	May	CAHN
>A>	@ SUN PHARMA GLOBAL	5MG	A090058 001	May 05, 2010	May	CAHN
>A>	@	10MG	A090058 002	May 05, 2010	May	CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	ASTRAZENECA	10MG/ML	A081002 001	Jul 30, 1993	May	CAHN
>A>	AP	BAXTER HLTHCARE CORP	10MG/ML	A081002 001	Jul 30, 1993	May	CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

>D>	AA	ALEMBIC LTD	400MG	A090122 002	Feb 18, 2009	May	CAHN
>A>	AA	ALEMBIC PHARMS LTD	400MG	A090122 002	Feb 18, 2009	May	CAHN
>A>	AA	TARO	200MG	A200998 001	May 23, 2011	May	NEWA
>A>	AA		400MG	A200998 002	May 23, 2011	May	NEWA

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

>A>	+	AQUA PHARMS	2%;0.01%	N020922 001	Dec 10, 1999	May	CAHN
>D>	+	STIEFEL LABS INC	2%;0.01%	N020922 001	Dec 10, 1999	May	CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	SANDOZ	500MG/VIAL	A091201 001	Mar 29, 2011	Mar	NEWA	
AP		1GM/VIAL	A091201 002	Mar 29, 2011	Mar	NEWA	
	MERREM						
AP	+	ASTRAZENECA	500MG/VIAL	N050706 003	Jun 21, 1996	Mar	CTNA
AP	+		1GM/VIAL	N050706 001	Jun 21, 1996	Mar	CTNA

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MYLAN	500MG	A075973 001	Jan 25, 2002	Feb	CAHN
AB		850MG	A075973 002	Jan 25, 2002	Feb	CAHN
AB		1GM	A075973 003	Jan 25, 2002	Feb	CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB	TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Feb	CFTG
AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Feb	CFTG

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	MYLAN	500MG;EQ 15MG BASE	A090406 001	Feb 25, 2011	Feb	NEWA
AB		850MG;EQ 15MG BASE	A090406 002	Feb 25, 2011	Feb	NEWA

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

AB	+ NOVARTIS	0.2MG	N006035 003		Apr	CTEC
AB	NOVEL LABS INC	0.2MG	A091577 001	May 02, 2011	Apr	NEWA

METHYLERGONOVINE MALEATE

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB	JUBILANT CADISTA	4MG	A040189 001	Oct 31, 1997	Jan	CAHN
AB		8MG	A040189 002	Oct 31, 1997	Jan	CAHN
AB		16MG	A040189 003	Jul 20, 2007	Jan	CAHN
AB		32MG	A040189 004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HEMOPARM	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Apr	CAHN
AP		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Apr	CAHN
	@ HOSPIRA	EQ 500MG BASE/VIAL	A089173 001	Aug 18, 1987	Feb	DISC
	@	EQ 1GM BASE/VIAL	A089174 001	Aug 18, 1987	Feb	DISC

METRONIDAZOLE

GEL; TOPICAL

METRONIDAZOLE

AB	G AND W LABS INC	0.75%	A078178 001	Jan 19, 2011	Jan	NEWA
----	------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

METRONIDAZOLE

>D>	AB	ALEMBIC LTD	250MG	A079067 001	Mar 13, 2009	May	CAHN
>D>	AB		500MG	A079067 002	Mar 13, 2009	May	CAHN
>A>	AB	ALEMBIC PHARMS LTD	250MG	A079067 001	Mar 13, 2009	May	CAHN
>A>	AB		500MG	A079067 002	Mar 13, 2009	May	CAHN

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

	+ ASTELLAS	100MG/VIAL	N021506 003	Jun 27, 2006	Jan	CRLD
--	------------	------------	-------------	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDOZALAM HYDROCHLORIDE

AP	SAGENT STRIDES	EQ 1MG BASE/ML	A090316 001	May 04, 2011	Apr	NEWA
AP		EQ 5MG BASE/ML	A090316 002	May 04, 2011	Apr	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

	@ HOSPIRA	EQ 1MG BASE/ML	A075884 001	May 28, 2002	Feb	DISC
--	-----------	----------------	-------------	--------------	-----	------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB	ACTAVIS ELIZABETH	15MG	A077959 001	Feb 14, 2011	Jan	NEWA
AB		30MG	A077959 002	Feb 14, 2011	Jan	NEWA
AB		45MG	A077959 003	Feb 14, 2011	Jan	NEWA

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

>D>	EKR THERAP	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CRLD
>A>	+	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CRLD
>D>	+	15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	DISC
>A>	@	15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	DISC

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

>A>	AB	GLENMARK PHARMS	2%	A090480 001	Jun 08, 2011	May	NEWA
-----	----	-----------------	----	-------------	--------------	-----	------

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

+ GLAXOSMITHKLINE EQ 2% BASE

N050746 001	Dec 11, 1997	Jan	CDFR
-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	LUPIN LTD	500MG	A090445 001	Jan 12, 2011	Jan	NEWA	
AB		750MG	A090445 002	Jan 12, 2011	Jan	NEWA	
>A>	AB	WATSON LABS	500MG	A091083 001	Jun 13, 2011	May	NEWA
>A>	AB		750MG	A091083 002	Jun 13, 2011	May	NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP	INSTITUTO BIOCHEMICO	EQ 10GM BASE/VIAL	A090005 001	Apr 20, 2011	Apr	NEWA	
AP	+	SANDOZ	EQ 10GM BASE/VIAL	A062527 004	Aug 02, 1984	Apr	CTEC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	ELITE LABS	50MG	A075274 001	May 26, 1999	Feb	CAHN
----	------------	------	-------------	--------------	-----	------

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	MARKSANS PHARMA	250MG	A091416 001	Feb 14, 2011	Jan	NEWA
AB		375MG	A091416 002	Feb 14, 2011	Jan	NEWA
AB		500MG	A091416 003	Feb 14, 2011	Jan	NEWA

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

AB	APOTEX CORP	EQ 1MG BASE	A091373 001	Apr 22, 2011	Apr	NEWA
AB		EQ 2.5MG BASE	A091373 002	Apr 22, 2011	Apr	NEWA
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552 001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	INDICUS PHARMA	EQ 1MG BASE	A200502 001	Feb 28, 2011	Feb	NEWA
AB		EQ 2.5MG BASE	A200502 002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB	WATSON LABS	60MG	A077462 001	Mar 30, 2011	Mar	NEWA
AB		120MG	A077462 002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

VIRAMUNE XR

+	BOEHRINGER INGELHEIM	400MG	N201152 001	Mar 25, 2011	Mar	NEWA
---	----------------------	-------	-------------	--------------	-----	------

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

>D>	+	EKR THERAP	45MG	N020005 002	Feb 21, 1992	May	DISC
>A>	@		45MG	N020005 002	Feb 21, 1992	May	DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1	VALEANT INTL	30MG	A075269 001	Dec 04, 2000	Apr	CAHN
AB2		30MG	A075289 002	Feb 06, 2001	Apr	CAHN
AB1		60MG	A075269 002	Dec 04, 2000	Apr	CAHN
AB2		60MG	A075289 001	Sep 27, 2000	Apr	CAHN
AB1		90MG	A076070 001	Aug 16, 2002	Apr	CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB	MYLAN	8.5MG	A091001 001	Jan 26, 2011	Jan	NEWA	
AB		17MG	A091001 002	Jan 26, 2011	Jan	NEWA	
AB		25.5MG	A091001 003	Jan 26, 2011	Jan	NEWA	
AB		34MG	A091001 004	Jan 26, 2011	Jan	NEWA	
	SULAR						
AB	+	SHIONOGI PHARMA	8.5MG	N020356 008	Jan 02, 2008	Jan	CFTG
AB	+		17MG	N020356 007	Jan 02, 2008	Jan	CFTG
AB		25.5MG	N020356 006	Jan 02, 2008	Jan	CFTG	
AB	+		34MG	N020356 005	Jan 02, 2008	Jan	CFTG

NITROFURANTOINSUSPENSION; ORAL
FURADANTIN

AB	+	SHIONOGI INC	25MG/5ML	N009175 001		Apr	CFTG
AB		AMNEAL PHARMS	25MG/5ML	A201679 001	May 11, 2011	Apr	NEWA

NIZATIDINECAPSULE; ORAL
NIZATIDINE

AB		MYLAN	150MG	A075934 001	Jul 09, 2002	Feb	CAHN
AB			300MG	A075934 002	Jul 09, 2002	Feb	CAHN

NYSTATINSUSPENSION; ORAL
NYSTATIN

AA		VISTAPHARM	100,000 UNITS/ML	A065422 001	Mar 07, 2011	Feb	NEWA
----	--	------------	------------------	-------------	--------------	-----	------

OCTREOTIDE ACETATEINJECTABLE; INJECTION
OCTREOTIDE ACETATE

AP		WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986 001	May 11, 2011	Apr	NEWA
AP			EQ 1MG BASE/ML	A090986 002	May 11, 2011	Apr	NEWA
AP		BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198 001	Feb 10, 2011	Jan	NEWA
AP			EQ 0.1MG BASE/ML	A079198 002	Feb 10, 2011	Jan	NEWA
AP			EQ 0.5MG BASE/ML	A079198 003	Feb 10, 2011	Jan	NEWA
AP		WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985 001	May 11, 2011	Apr	NEWA
AP			EQ 0.1MG BASE/ML	A090985 002	May 11, 2011	Apr	NEWA
AP			EQ 0.5MG BASE/ML	A090985 003	May 11, 2011	Apr	NEWA

ONDANSETRONTABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

AB		RANBAXY	4MG	A078602 001	Feb 24, 2011	Feb	NEWA
AB			8MG	A078602 002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

>D>	AP	AKORN STRIDES	EQ 2MG BASE/ML	A078257 001	Apr 23, 2008	May	CAHN
>A>	AP	PFIZER	EQ 2MG BASE/ML	A078257 001	Apr 23, 2008	May	CAHN
	AP	TEVA	EQ 2MG BASE/ML	A076876 001	Nov 22, 2006	Jan	CMFD

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP	+	HOSPIRA	EQ 0.64MG BASE/ML	A077348 001	Feb 01, 2007	Apr	CRLD
----	---	---------	-------------------	-------------	--------------	-----	------

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	AKORN STRIDES	EQ 2MG BASE/ML	A078244 001	Apr 23, 2008	May	CAHN
>A>	AP	PFIZER	EQ 2MG BASE/ML	A078244 001	Apr 23, 2008	May	CAHN

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA		AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483 001	Jan 31, 2011	Jan	NEWA
AA		SILARX	EQ 4MG BASE/5ML	A091342 001	Jan 27, 2011	Jan	NEWA

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

AB		TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011	Mar	NEWA
----	--	------	-------------	-------------	--------------	-----	------

TABLET; ORAL

ONDANSERTRON HYDROCHLORIDE

AB	TARO	EQ 8MG BASE	A077729 002	Mar 28, 2011	Mar	NEWA
AB		EQ 24MG BASE	A077729 003	Mar 28, 2011	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	SANDOZ	50MG/10ML (5MG/ML)	A078817 001	Jan 24, 2011	Jan	NEWA
AP		50MG/VIAL	A090849 001	Apr 28, 2011	Apr	NEWA
AP		100MG/VIAL	A090849 002	Apr 28, 2011	Apr	NEWA
AP		100MG/20ML (5MG/ML)	A078817 002	Jan 24, 2011	Jan	NEWA

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB	MYLAN	600MG	A075847 001	Feb 28, 2001	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB	COASTAL PHARMS	5MG	A091313 001	Feb 18, 2011	Feb	NEWA
AB		15MG	A091313 002	Feb 18, 2011	Feb	NEWA
AB		30MG	A091313 003	Feb 18, 2011	Feb	NEWA
AB	RHODES PHARMS	5MG	A091490 001	Mar 09, 2011	Feb	NEWA
AB		10MG	A091490 002	Mar 09, 2011	Feb	NEWA
AB		15MG	A091490 003	Mar 09, 2011	Feb	NEWA
AB		20MG	A091490 004	Mar 09, 2011	Feb	NEWA
AB		30MG	A091490 005	Mar 09, 2011	Feb	NEWA

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

>D>	+	ALAVEN PHARM	50MG	N016848 001		May	CAHN
>A>	+	MEDA PHARMS	50MG	N016848 001		May	CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	TEVA	5MG	A091443 002	Feb 15, 2011	Jan	NEWA
AB		10MG	A091443 001	Feb 15, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS

@

7.5MG

15MG

N021610 005 Feb 29, 2008 Feb DISC

N021610 006 Feb 29, 2008 Feb DISC

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

>D>	AP	GENERAMEDIX	30MG/10ML (3MG/ML)	A078373 001	Dec 23, 2008	May	CAHN
>D>	AP		90MG/10ML (9MG/ML)	A078373 002	Dec 23, 2008	May	CAHN
>A>	AP	MUSTAFA NEVZAT	30MG/10ML (3MG/ML)	A078373 001	Dec 23, 2008	May	CAHN
>A>	AP		90MG/10ML (9MG/ML)	A078373 002	Dec 23, 2008	May	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797 001	Feb 07, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090797 002	Feb 07, 2011	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ 20MG BASE	A077619 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A077619 002	Jan 19, 2011	Jan	NEWA
AB	KUDCO IRELAND	EQ 20MG BASE	A078281 001	Jan 20, 2011	Jan	NEWA
AB		EQ 40MG BASE	A078281 002	Jan 20, 2011	Jan	NEWA
AB	MATRIX LABS LTD	EQ 20MG BASE	A090970 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090970 002	Jan 19, 2011	Jan	NEWA
AB	TORRENT PHARMS	EQ 20MG BASE	A090074 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090074 002	Jan 19, 2011	Jan	NEWA
AB	WOCKHARDT	EQ 20MG BASE	A091231 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A091231 002	Jan 19, 2011	Jan	NEWA

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

>D>	@ KING PHARMS	EQ 250MG BASE	A062310 001		May	CAHN
>A>	@ MONARCH PHARMS	EQ 250MG BASE	A062310 001		May	CAHN

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB	MYLAN	EQ 37.5MG BASE	A091427 001	Apr 14, 2011	Apr	NEWA
AB	+ PAXIL CR					
AB	+ GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936 003	Dec 06, 2000	Apr	CTEC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB	VALEANT INTL	400MG	A075028 001	Jul 20, 1998	Apr	CAHN
----	--------------	-------	-------------	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

>A>	AA ELITE LABS	37.5MG	A200272 001	Jan 31, 2011	May	CAHN
>D>	AA EPIC PHARMA LLC	37.5MG	A200272 001	Jan 31, 2011	May	CAHN
AA		37.5MG	A200272 001	Jan 31, 2011	Jan	NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

>D>	AP HIKMA FARMACEUTICA	50MG/ML	A040573 001	Sep 13, 2006	May	CAHN
>A>	AP X-GEN PHARMS	50MG/ML	A040573 001	Sep 13, 2006	May	CAHN

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

CARPINE

>D>	ALCON	1%	N200890 001	Jun 22, 2010	May	CTNA
>D>		2%	N200890 002	Jun 22, 2010	May	CTNA
>D>	+	4%	N200890 003	Jun 22, 2010	May	CTNA
>A>	ISOPTO CARPINE					
>A>	ALCON RES	1%	N200890 001	Jun 22, 2010	May	CTNA

SOLUTION; OPHTHALMIC

>A>		ISOPTO CARPINE							
>A>		ALCON RES	2%	N200890	002	Jun 22, 2010	May	CTNA	
>A>		+	4%	N200890	003	Jun 22, 2010	May	CTNA	

PIPERACILLIN SODIUM; TAZOBACTAM SODIUMINJECTABLE; INJECTIONPIPERACILLIN AND TAZOBACTAM

>A>	AP	AUROBINDO PHARMA LTD	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065498	001	May 23, 2011	May	NEWA	
>A>	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065498	002	May 23, 2011	May	NEWA	
>A>	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065498	003	May 23, 2011	May	NEWA	
	AP	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Jan	CAHN	
	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Jan	CAHN	
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Jan	CAHN	
	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Jan	CAHN	
>A>	AP	INSTITUTO BIOCHEMICO	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	May	NEWA	
>A>	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	May	NEWA	
>A>	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	May	NEWA	
>A>	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	May	NEWA	

PIROXICAMCAPSULE; ORALPIROXICAM

		@ MYLAN	10MG	A074043	001	Sep 22, 1992	Feb	CAHN	
		@	20MG	A074043	002	Sep 22, 1992	Feb	CAHN	

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORALPOTASSIUM CHLORIDE

>A>	AB	PADDOCK LABS	8MEQ	A200185	001	May 18, 2011	May	NEWA	
>A>	AB		10MEQ	A200185	002	May 18, 2011	May	NEWA	

PREDNISOLONE SODIUM PHOSPHATESOLUTION; ORALPREDNISOLONE SODIUM PHOSPHATE

>D>	AA	VINTAGE	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007	May	DISC	
>A>		@ VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007	May	DISC	

PREDNISONETABLET; ORALPREDNISONE

	AB	JUBILANT CADISTA	1MG	A040611	001	Jun 06, 2005	Jan	CAHN	
	AB		5MG	A040362	002	Aug 29, 2001	Jan	CAHN	
	AB		10MG	A040362	001	Aug 29, 2001	Jan	CAHN	
	AB		20MG	A040362	003	Jun 29, 2005	Jan	CAHN	

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268 001	Feb 27, 1998	Jan	CAHN
AB		EQ 10MG BASE	A040268 002	Feb 27, 1998	Jan	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

>D>	AP	HIKMA FARMACEUTICA	25MG/ML	A040737 001	Apr 24, 2008	May	CAHN
>D>	AP		50MG/ML	A040737 002	Apr 24, 2008	May	CAHN
>A>	AP	X-GEN PHARMS	25MG/ML	A040737 001	Apr 24, 2008	May	CAHN
>A>	AP		50MG/ML	A040737 002	Apr 24, 2008	May	CAHN

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+	ROXANE	15MG	A080927 002		Jan	CMFD
---	--------	------	-------------	--	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

@	XANODYNE PHARM	65MG	N010997 003		Jan	DISC
---	----------------	------	-------------	--	-----	------

PROPOXYPHENE HYDROCHLORIDE

@	TEVA	65MG	A088615 001	Oct 22, 1984	Mar	DISC
---	------	------	-------------	--------------	-----	------

@	VINTAGE PHARMS	65MG	A040908 001	Jul 17, 2009	Mar	DISC
---	----------------	------	-------------	--------------	-----	------

@	WEST WARD	65MG	A083501 001		Jan	DISC
---	-----------	------	-------------	--	-----	------

PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVON-N

@	XANODYNE PHARM	100MG	N016862 002		Jan	DISC
---	----------------	-------	-------------	--	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	60MG	A090321 001	Mar 25, 2011	Mar	NEWA
AB		80MG	A090321 002	Mar 25, 2011	Mar	NEWA
AB		120MG	A090321 003	Mar 25, 2011	Mar	NEWA
AB		160MG	A090321 004	Mar 25, 2011	Mar	NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	MYLAN	60MG	A070213 005	Apr 08, 2011	Mar	NEWA
----	-------	------	-------------	--------------	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005	Feb	CAHN
AB		EQ 10MG BASE	A076036 002	Jan 28, 2005	Feb	CAHN
AB		EQ 20MG BASE	A076036 003	Jan 28, 2005	Feb	CAHN
AB		EQ 40MG BASE	A076036 004	Jan 28, 2005	Feb	CAHN

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

>A>	AB	AUROBINDO PHARMA LTD	1.25MG	A091604 001	Jun 08, 2011	May	NEWA
>A>	AB		2.5MG	A091604 002	Jun 08, 2011	May	NEWA
>A>	AB		5MG	A091604 003	Jun 08, 2011	May	NEWA
>A>	AB		10MG	A091604 004	Jun 08, 2011	May	NEWA

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

@ MYLAN

EQ 150MG BASE

A075564 001 Oct 27, 2000 Feb CAHN

@

EQ 300MG BASE

A075564 002 Oct 27, 2000 Feb CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA HI TECH PHARMA

EQ 15MG BASE/ML

A091078 001 Mar 22, 2011 Mar NEWA

>A>

AA

TARO

EQ 15MG BASE/ML

A077476 001 Jun 13, 2011 May NEWA

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AB MYLAN

EQ 150MG BASE

A074023 001 Aug 22, 1997 Feb CAHN

AB

EQ 300MG BASE

A074023 002 Aug 22, 1997 Feb CAHN

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

>D>

AP

AKORN STRIDES

600MG/VIAL

A065421 001 May 22, 2008 May CAHN

>A>

AP

PFIZER

600MG/VIAL

A065421 001 May 22, 2008 May CAHN

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+ SALIX PHARMS

550MG

N022554 001 Mar 24, 2010 Feb CRLD

>A>

RILPIVIRINE HYDROCHLORIDE

>A>

TABLET; ORAL

>A>

EDURANT

>A>

+ TIBOTEC

EQ 25MG BASE

N202022 001 May 20, 2011 May NEWA

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

>A>

AA

AMNEAL PHARMS

1MG/ML

A091384 001 May 25, 2011 May NEWA

AA

TARO

1MG/ML

A090347 001 Feb 07, 2011 Jan NEWA

TABLET; ORAL

RISPERIDONE

>A>

AB

CIPLA

0.25MG

A077543 001 May 18, 2011 May NEWA

>A>

AB

0.5MG

A077543 002 May 18, 2011 May NEWA

>A>

AB

1MG

A077543 003 May 18, 2011 May NEWA

>A>

AB

2MG

A077543 004 May 18, 2011 May NEWA

>A>

AB

3MG

A077543 005 May 18, 2011 May NEWA

>A>

AB

4MG

A077543 006 May 18, 2011 May NEWA

@ RATIOPHARM

0.25MG

A077784 001 Jun 08, 2010 Feb DISC

@

0.5MG

A077784 002 Jun 08, 2010 Feb DISC

@

1MG

A077784 003 Jun 08, 2010 Feb DISC

@

2MG

A077784 004 Jun 08, 2010 Feb DISC

TABLET; ORAL

RISPERIDONE

@ RATIOPHARM

3MG

A077784 005 Jun 08, 2010 Feb DISC

@

4MG

A077784 006 Jun 08, 2010 Feb DISC

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB MYLAN

0.5MG

A091537 001 Mar 30, 2011 Mar NEWA

AB

1MG

A091537 002 Mar 30, 2011 Mar NEWA

AB

2MG

A091537 003 Mar 30, 2011 Mar NEWA

AB

3MG

A091537 004 Mar 30, 2011 Mar NEWA

AB

4MG

A091537 005 Mar 30, 2011 Mar NEWA

AB WATSON LABS FLORIDA

0.5MG

A076996 001 Apr 19, 2011 Apr NEWA

AB

1MG

A076996 002 Apr 19, 2011 Apr NEWA

AB

2MG

A076996 003 Apr 19, 2011 Apr NEWA

AB

3MG

A076996 004 Apr 19, 2011 Apr NEWA

AB

4MG

A076996 005 Apr 19, 2011 Apr NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP SAGENT STRIDES

50MG/5ML (10MG/ML)

A091458 001 Jul 28, 2010 Jan CAHN

AP

100MG/10ML (10MG/ML)

A091458 002 Jul 28, 2010 Jan CAHN

ROFLUMILAST

TABLET; ORAL

DALIRESP

+ FOREST RES INST INC

500MCG

N022522 001 Feb 28, 2011 Feb NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

>D> AB HUAHAI US INC

EQ 0.25MG BASE

A078110 001 May 05, 2008 May CAHN

>D> AB

EQ 0.5MG BASE

A078110 002 May 05, 2008 May CAHN

>D> AB

EQ 1MG BASE

A078110 003 May 05, 2008 May CAHN

>D> AB

EQ 2MG BASE

A078110 004 May 05, 2008 May CAHN

>D> AB

EQ 3MG BASE

A078110 005 May 05, 2008 May CAHN

>D> AB

EQ 4MG BASE

A078110 006 May 05, 2008 May CAHN

>A> AB PRINSTON PHARM LLC

EQ 0.25MG BASE

A078110 001 May 05, 2008 May CAHN

>A> AB

EQ 0.5MG BASE

A078110 002 May 05, 2008 May CAHN

>A> AB

EQ 1MG BASE

A078110 003 May 05, 2008 May CAHN

>A> AB

EQ 2MG BASE

A078110 004 May 05, 2008 May CAHN

>A> AB

EQ 3MG BASE

A078110 005 May 05, 2008 May CAHN

>A> AB

EQ 4MG BASE

A078110 006 May 05, 2008 May CAHN

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+ EISAI INC

40MG/ML

N201367 001 Mar 03, 2011 Mar NEWA

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+ MARATHON PHARMS

50MG

A086101 001 Oct 03, 1983 Jan CAHN

+

100MG

A086101 002 Oct 03, 1983 Jan CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@	ROXANE	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	DISC
---	--------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

	@	IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006	Apr	DISC
	@		EQ 50MG BASE	A075719	001	Jun 30, 2006	Apr	DISC
	@		EQ 100MG BASE	A075719	002	Jun 30, 2006	Apr	DISC
AB		MYLAN	EQ 25MG BASE	A076540	001	Mar 20, 2007	Feb	CAHN
AB			EQ 50MG BASE	A076540	002	Mar 20, 2007	Feb	CAHN
AB			EQ 100MG BASE	A076540	003	Mar 20, 2007	Feb	CAHN
	@	ROXANE	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	DISC
	@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	DISC
	@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	DISC

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

>D>	+	MEDIGENE	15%	N021902	001	Oct 31, 2006	May	CAHN
>A>	+	MEDIGENE AG	15%	N021902	001	Oct 31, 2006	May	CAHN

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955	001	Feb 18, 1999	Mar	CFTG
AB		SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE						
		GENERAMEDIX	62.5MG/5ML	A078215	001	Mar 31, 2011	Mar	NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F 18

	@	NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Apr	DISC
	+		10-200mCi/ML	N022494	001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Feb	CTNA
---	-------------	---	---------	-----	--------------	-----	------

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Jan	NEWA
---	-------------	---	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>A>	AA	PADDOCK LABS	15GM/60ML	A090590	001	May 13, 2011	May	NEWA
-----	----	--------------	-----------	---------	-----	--------------	-----	------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO PHARMS	0.9%	N022408	001	Jan 18, 2011	Jan	NEWA
---	----------------	------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN SUCCINATE

@	ROXANE	EQ 25MG BASE	A078241 001	Aug 10, 2009	Mar	DISC
@		EQ 50MG BASE	A078241 002	Aug 10, 2009	Mar	DISC
@		EQ 100MG BASE	A078241 003	Aug 10, 2009	Mar	DISC

>A> TELAPREVIR

>A> TABLET; ORAL

>A> INCIVEK

>A>	+	VERTEX PHARMS	375MG	N201917 001	May 23, 2011	May	NEWA
-----	---	---------------	-------	-------------	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB		JUBILANT CADISTA	EQ 1MG BASE	A075317 001	Dec 20, 2004	Jan	CAHN
AB			EQ 2MG BASE	A075317 002	Dec 20, 2004	Jan	CAHN
AB			EQ 5MG BASE	A075317 003	Dec 20, 2004	Jan	CAHN
AB			EQ 10MG BASE	A075317 004	Dec 20, 2004	Jan	CAHN

TERBINAFFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFFINE HYDROCHLORIDE

AB		MYLAN	EQ 250MG BASE	A077136 001	Jul 02, 2007	Feb	CAHN
	@	ROXANE	EQ 250MG BASE	A077223 001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL

TERBUTALINE SULFATE

AB	+	IMPAX LABS	5MG	A075877 002	Jun 26, 2001	Jan	CRLD
----	---	------------	-----	-------------	--------------	-----	------

TESTOSTERONE

GEL, METERED; TRANSDERMAL

ANDROGEL

+	ABBOTT PRODS	1.62% (20.25MG/1.25GM ACTIVATION)	N022309 001	Apr 29, 2011	Apr	NEWA
---	--------------	-----------------------------------	-------------	--------------	-----	------

FORTESTA

+	ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463 001	Dec 29, 2010	Mar	CPOT
---	-------------	-----------------------	-------------	--------------	-----	------

THEOPHYLLINE

SOLUTION; ORAL

THEOPHYLLINE

+	SILARX	80MG/15ML	A091156 001	Apr 13, 2011	Mar	NEWA
---	--------	-----------	-------------	--------------	-----	------

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

>D>	AP	HOSPIRA	100MG/ML	A040079 001	May 03, 1996	May	DISC
>A>		@	100MG/ML	A040079 001	May 03, 1996	May	DISC

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

AB		MYLAN	250MG	A075161 001	Sep 13, 1999	Feb	CAHN
----	--	-------	-------	-------------	--------------	-----	------

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	FERA PHARMS	0.3%	A065026 001	Sep 11, 2001	Mar	CAHN
----	-------------	------	-------------	--------------	-----	------

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191 001	Mar 09, 2011	Feb	NEWA
AP	SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284 001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS

TOPOTECAN

AP	HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582 001	Feb 02, 2011	Feb	NEWA
	SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199 001	Feb 25, 2011	Feb	NEWA
		EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199 002	Feb 25, 2011	Feb	NEWA
AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199 003	Feb 25, 2011	Feb	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	VINTAGE PHARMS	5MG	A090613 001	Mar 22, 2011	Mar	NEWA
AB		10MG	A090613 002	Mar 22, 2011	Mar	NEWA
AB		20MG	A090613 003	Mar 22, 2011	Mar	NEWA
AB		100MG	A090613 004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	50MG	A090404 001	Jan 31, 2011	Jan	NEWA
----	----------------------	------	-------------	--------------	-----	------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

>D>	+	ALCON	0.004%	N021257 001	Mar 16, 2001	May	DISC
>A>		@	0.004%	N021257 001	Mar 16, 2001	May	DISC

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

>A>	ANGELINI LABOPHARM	300MG	N022411 002	Feb 02, 2010	May	CAHN
>D>	LABOPHARM	300MG	N022411 002	Feb 02, 2010	May	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

>A>	AP	LUITPOLD	100MG/ML	A091330 001	Mar 08, 2011	May	CAHN
>D>	AP	PHARMAFORCE	100MG/ML	A091330 001	Mar 08, 2011	May	CAHN
	AP		100MG/ML	A091330 001	Mar 08, 2011	Feb	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

>A>	AP	LUITPOLD	100MG/ML	A091329 001	Mar 08, 2011	May	CAHN
>D>	AP	PHARMAFORCE	100MG/ML	A091329 001	Mar 08, 2011	May	CAHN
	AP		100MG/ML	A091329 001	Mar 08, 2011	Feb	NEWA

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

>A>	AB	NOVEL LABS INC	100MG	A091437 001	Jun 15, 2011	May	NEWA
-----	----	----------------	-------	-------------	--------------	-----	------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361 001	Aug 02, 2006	Feb	CAHN
AB		EQ 50MG BASE	A077361 002	Aug 02, 2006	Feb	CAHN
AB		EQ 100MG BASE	A077361 003	Aug 02, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370 001	Mar 16, 2011	Feb	NEWA
AB		EQ 1GM BASE	A090370 002	Mar 16, 2011	Feb	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

>D>	AP	AKORN STRIDES	EQ 500MG BASE/VIAL	A065397 001	Dec 30, 2008	May	CAHN
>D>	AP		EQ 1GM BASE/VIAL	A065397 002	Dec 30, 2008	May	CAHN
>D>	AP		EQ 5GM BASE/VIAL	A065432 001	Dec 30, 2008	May	CAHN
>A>	AP	PFIZER	EQ 500MG BASE/VIAL	A065397 001	Dec 30, 2008	May	CAHN
>A>	AP		EQ 1GM BASE/VIAL	A065397 002	Dec 30, 2008	May	CAHN
>A>	AP		EQ 5GM BASE/VIAL	A065432 001	Dec 30, 2008	May	CAHN

VANDETANIB

TABLET; ORAL

VANDETANIB

		IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Apr	NEWA
		+	300MG	N022405 002	Apr 06, 2011	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

>D>	AP	AKORN STRIDES	10MG/VIAL	A090243 001	May 11, 2010	May	CAHN
>D>	AP		20MG/VIAL	A090243 002	May 11, 2010	May	CAHN
>A>	AP	PFIZER	10MG/VIAL	A090243 001	May 11, 2010	May	CAHN
>A>	AP		20MG/VIAL	A090243 002	May 11, 2010	May	CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834 001	Apr 14, 2011	Apr	NEWA	
AB		EQ 75MG BASE	A200834 002	Apr 14, 2011	Apr	NEWA	
AB		EQ 150MG BASE	A200834 003	Apr 14, 2011	Apr	NEWA	
AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421 001	May 06, 2011	Apr	NEWA	
AB		EQ 75MG BASE	A078421 002	May 06, 2011	Apr	NEWA	
AB		EQ 150MG BASE	A078421 003	May 06, 2011	Apr	NEWA	
>A>	AB	MYLAN	EQ 37.5MG BASE	A078789 001	Jun 01, 2011	May	NEWA
>A>	AB		EQ 75MG BASE	A078789 002	Jun 01, 2011	May	NEWA
>A>	AB		EQ 150MG BASE	A078789 003	Jun 01, 2011	May	NEWA
>A>	AB	TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899 001	Jun 01, 2011	May	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

>A>	AB	TORRENT PHARMS LLC	EQ 75MG BASE	A090899 002	Jun 01, 2011	May	NEWA
>A>	AB		EQ 150MG BASE	A090899 003	Jun 01, 2011	May	NEWA
	AB	VALEANT INTL	EQ 37.5MG BASE	A090071 001	Apr 15, 2011	Apr	NEWA
	AB		EQ 75MG BASE	A090071 002	Apr 15, 2011	Apr	NEWA
	AB		EQ 150MG BASE	A090071 003	Apr 15, 2011	Apr	NEWA
	AB	WOCKHARDT	EQ 37.5MG BASE	A078865 001	Apr 14, 2011	Apr	NEWA
	AB		EQ 75MG BASE	A078865 002	Apr 14, 2011	Apr	NEWA
	AB		EQ 150MG BASE	A078865 003	Apr 14, 2011	Apr	NEWA
	AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174 001	Apr 14, 2011	Apr	NEWA
	AB		EQ 75MG BASE	A090174 002	Apr 14, 2011	Apr	NEWA
	AB		EQ 150MG BASE	A090174 003	Apr 14, 2011	Apr	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VILIBRYD

>A>		FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	May	CAHN
>A>			20MG	N022567 002	Jan 21, 2011	May	CAHN
>A>	+		40MG	N022567 003	Jan 21, 2011	May	CAHN
>D>		TROVIS PHARMS	10MG	N022567 001	Jan 21, 2011	May	CAHN
			10MG	N022567 001	Jan 21, 2011	Jan	NEWA
>D>			20MG	N022567 002	Jan 21, 2011	May	CAHN
			20MG	N022567 002	Jan 21, 2011	Jan	NEWA
>D>	+		40MG	N022567 003	Jan 21, 2011	May	CAHN
	+		40MG	N022567 003	Jan 21, 2011	Jan	NEWA

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

@ APP PHARMS

1MG/ML

A076401 001 Oct 28, 2003 Jan DISC

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

>A>	AB	INVAGEN PHARMS	1MG	A090935 001	May 25, 2011	May	NEWA
>A>	AB		2MG	A090935 002	May 25, 2011	May	NEWA
>A>	AB		2.5MG	A090935 003	May 25, 2011	May	NEWA
>A>	AB		3MG	A090935 004	May 25, 2011	May	NEWA
>A>	AB		4MG	A090935 005	May 25, 2011	May	NEWA
>A>	AB		5MG	A090935 006	May 25, 2011	May	NEWA
>A>	AB		6MG	A090935 007	May 25, 2011	May	NEWA
>A>	AB		7.5MG	A090935 008	May 25, 2011	May	NEWA
>A>	AB		10MG	A090935 009	May 25, 2011	May	NEWA

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

AP LUITPOLD 10MG/ML

A091457 001 May 06, 2010 Feb CAHN

TABLET; ORAL

ZIDOVUDINE

@ MATRIX LABS LTD

100MG

N200732 001 Feb 23, 2011 Feb NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	MYLAN	5MG	A078016 001	Apr 23, 2007	Feb	CAHN
AB		10MG	A078016 002	Apr 23, 2007	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB	ANCHEN PHARMS	6.25MG	A078148 002	Apr 14, 2011	Apr	NEWA
AB	SYNTHON PHARMS	6.25MG	A078483 001	Apr 12, 2011	Apr	NEWA

OTC DRUG PRODUCT LIST - 31ST EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

2-1

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	SILARX	5MG/5ML	A091130	001	Apr 22, 2011	Apr	NEWA
>A>	TARO	5MG/5ML	A201546	001	May 20, 2011	May	NEWA
	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
	SILARX	5MG/5ML	A091130	002	Apr 22, 2011	Apr	NEWA
>A>	TARO	5MG/5ML	A201546	002	May 20, 2011	May	NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN
	CHLORAPREP SINGLE SWABSTICK						
+	CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN
	CHLORAPREP TRIPLE SWABSTICK						
+	CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Apr	NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

	MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN
--	-------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA
	CHILDREN'S ALLEGRA HIVES						
+	SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA
	CHILDREN'S ALLEGRA HIVES						
+	SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA

TABLET; ORAL

ALLEGRA ALLERGY

	SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
+		180MG	N020872	010	Jan 24, 2011	Jan	NEWA
	ALLEGRA HIVES						
	SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
+		180MG	N020872	009	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA ALLERGY

	SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA
--	-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

	SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA
--	-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011	Mar	NEWA
	TEVA	30MG	A076447	004	Apr 13, 2011	Mar	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011	Mar	NEWA
	TEVA	30MG	A076447	005	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011	Mar	NEWA
--	--------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	180MG	A076502 008	Apr 12, 2011	Mar	NEWA
TEVA	60MG	A076447 006	Apr 13, 2011	Mar	NEWA
	180MG	A076447 008	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502 007	Apr 12, 2011	Mar	NEWA
	180MG	A076502 009	Apr 12, 2011	Mar	NEWA
TEVA	60MG	A076447 007	Apr 13, 2011	Mar	NEWA
	180MG	A076447 009	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	60MG;120MG	N020786 002	Jan 24, 2011	Jan	NEWA
---------------------	------------	-------------	--------------	-----	------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	180MG;240MG	N021704 002	Jan 24, 2011	Jan	NEWA
---------------------	-------------	-------------	--------------	-----	------

IBUPROFEN

TABLET; ORAL

IBUPROFEN

>D>	ADVENT PHARMS	200MG	A076460 001	Nov 26, 2003	May	CAHN
>A>	AVEMA PHARMA	200MG	A076460 001	Nov 26, 2003	May	CAHN
	MARKSANS PHARMA	200MG	A091237 001	Feb 08, 2011	Jan	NEWA
		200MG	A091239 001	Feb 01, 2011	Jan	NEWA
	MERRO PHARM	200MG	A070985 001	Oct 02, 1987	Jan	CAHN
	SVADS HOLDINGS SA	200MG	A079129 001	Mar 28, 2011	Mar	NEWA
		200MG	A091355 001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN N

+ NOVO NORDISK INC	100 UNITS/ML	N019959 001	Jul 01, 1991	Jan	CRLD
--------------------	--------------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

+ TEVA WOMENS	0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN
---------------	--------	-------------	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL

LOPERAMIDE HYDROCHLORIDE

>A>	PERRIGO R AND D	1MG/7.5ML	A091292 001	May 20, 2011	May	NEWA
-----	-----------------	-----------	-------------	--------------	-----	------

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MINOXIDIL

PERRIGO ISRAEL	5%	A091344 001	Apr 28, 2011	Apr	NEWA
----------------	----	-------------	--------------	-----	------

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

>A>	MARKSANS PHARMA	EQ 200MG BASE	A090545 001	Mar 16, 2011	Feb	NEWA
	RANBAXY LABS LTD	EQ 200MG BASE	A091183 001	May 20, 2011	May	NEWA

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

ANBEX

65MG

N018664 002 May 12, 2011 Apr NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN

EQ 75MG BASE

A075497 001 Jan 14, 2000 Feb CAHN

PERRIGO R AND D

EQ 150MG BASE

A091429 001 May 11, 2011 Apr NEWA

EQ 150MG BASE

A091429 002 May 11, 2011 Apr NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2011

NO MAY 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N202379 001	>A> 5604213	Feb 18, 2014	DS DP U-1126		NCE	Apr 28, 2016
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	7868044	Mar 12, 2023	U-1078			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 001					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 002					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 003					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 004					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	5250542	Mar 29, 2016	DS DP U-878			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 005					PC	Jul 02, 2011
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 006					PC	Jul 02, 2011
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303 001	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303 006	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 001					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 002					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 003					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 004					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 005					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 006					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021713 001					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021729 002					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021729 003					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021866 001					I-633	Feb 16, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 003					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 004					D-130	Feb 04, 2014
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZITHROMYCIN - ZMAX</u>						
N050797 001	7887844	Feb 14, 2024	DP			
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	>A> 7012066	Feb 22, 2022	DS DP U-1128		>A> NCE	May 13, 2016
	>A> 7772178	Nov 11, 2027	DP U-1128			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	7897646	Sep 09, 2018	U-1118			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 001	>A> 5326570	Jul 23, 2011	U-215			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 002	>A> 5326570	Jul 23, 2011	U-215			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 003	>A> 5326570	Jul 23, 2011	U-215			
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5760068	Jun 02, 2015	U-672			
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	>A> 7935093	Oct 02, 2027	DP U-1022			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N021441 001	7863287	Feb 28, 2027	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001					I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002					I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003					I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 001	4847265	Nov 17, 2011	DS DP		>A> M-61	May 06, 2014
	4847265*PED	May 17, 2012			>A> PED	Nov 06, 2014
	5576328	Jan 31, 2014	U-432	Y		
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 002	4847265	Nov 17, 2011	DS DP		>A> M-61	May 06, 2014
	4847265*PED	May 17, 2012			>A> PED	Nov 06, 2014
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N021642 001	>A> 7879349	Jun 01, 2024	DP U-1152			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	>A> 5843946	Dec 01, 2015	DP U-903		>A> D-129	Dec 13, 2013
	>A> 5843946	Dec 01, 2015	DP U-935		>A> D-119	Dec 18, 2011
	>A> 5843946	Dec 01, 2015	DP U-744		>A> I-578	Oct 21, 2011
	>A> 5843946*PED	Jun 01, 2016			>A> NCE	Jun 23, 2011
	>A> 6037157	Jun 26, 2016	U-935		>A> PED	Jun 13, 2014
	>A> 6037157*PED	Dec 26, 2016			>A> PED	Jun 18, 2012
	>A> 6248775	Aug 13, 2014	DS		>A> PED	Apr 21, 2012
	>A> 6248775*PED	Feb 13, 2015			>A> PED	Dec 23, 2011
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	>A> 6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7470506*PED	Dec 23, 2019				
	>A> 7700645	Dec 26, 2026	DS DP			
	>A> 7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	>A> 5843946	Dec 01, 2015	DP U-903		>A> D-129	Dec 13, 2013
	>A> 5843946	Dec 01, 2015	DP U-935		>A> D-119	Dec 18, 2011
	>A> 5843946	Dec 01, 2015	DP U-744		>A> I-578	Oct 21, 2011
	>A> 5843946*PED	Jun 01, 2016			>A> NCE	Jun 23, 2011
	>A> 6037157	Jun 26, 2016	U-935		>A> PED	Jun 13, 2014
	>A> 6037157*PED	Dec 26, 2016			>A> PED	Jun 18, 2012
	>A> 6248775	Aug 13, 2014	DS		>A> PED	Apr 21, 2012
	>A> 6248775*PED	Feb 13, 2015			>A> PED	Dec 23, 2011
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	>A> 6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7470506*PED	Dec 23, 2019				
	>A> 7700645	Dec 26, 2026	DS DP			
	>A> 7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	>A> 5843946	Dec 01, 2015	DP U-903		>A> D-129	Dec 13, 2013
	>A> 5843946	Dec 01, 2015	DP U-935		>A> D-119	Dec 18, 2011
	>A> 5843946	Dec 01, 2015	DP U-744		>A> D-118	Oct 21, 2011
	>A> 5843946*PED	Jun 01, 2016			>A> I-578	Oct 21, 2011
	>A> 6037157	Jun 26, 2016	U-935		>A> NCE	Jun 23, 2011
	>A> 6037157*PED	Dec 26, 2016			>A> PED	Jun 13, 2014
	>A> 6248775	Aug 13, 2014	DS		>A> PED	Jun 18, 2012
	>A> 6248775*PED	Feb 13, 2015			>A> PED	Apr 21, 2012
	>A> 6335460	Aug 25, 2012	DS DP U-935		>A> PED	Dec 23, 2011
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7470506*PED	Dec 23, 2019				
	>A> 7700645	Dec 26, 2026	DS DP			
	>A> 7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	>A> 5843946	Dec 01, 2015	DP U-935		>A> D-129	Dec 13, 2013
	>A> 5843946*PED	Jun 01, 2016			>A> D-119	Dec 18, 2011
	>A> 6037157	Jun 26, 2016	U-935		>A> NS	Dec 18, 2011
	>A> 6037157*PED	Dec 26, 2016			>A> NCE	Jun 23, 2011
	>A> 6248775	Aug 13, 2014	DS		>A> PED	Jun 13, 2014
	>A> 6248775*PED	Feb 13, 2015			>A> PED	Jun 18, 2012
	>A> 6335460	Aug 25, 2012	DS DP U-935		>A> PED	Dec 23, 2011
	>A> 6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7470506*PED	Dec 23, 2019				
	>A> 7700645	Dec 26, 2026	DS DP			
	>A> 7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	>A> 5843946	Dec 01, 2015	DP U-935		>A> D-129	Dec 13, 2013
	>A> 5843946*PED	Jun 01, 2016			>A> D-119	Dec 18, 2011
	>A> 6037157	Jun 26, 2016	U-935		>A> NS	Dec 18, 2011
	>A> 6037157*PED	Dec 26, 2016			>A> NCE	Jun 23, 2011
	>A> 6248775	Aug 13, 2014	DS		>A> PED	Jun 13, 2014
	>A> 6248775*PED	Feb 13, 2015			>A> PED	Jun 18, 2012
	>A> 6335460	Aug 25, 2012	DS DP U-935		>A> PED	Dec 23, 2011
	>A> 6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7470506*PED	Dec 23, 2019				
	>A> 7700645	Dec 26, 2026	DS DP			
	>A> 7700645*PED	Jun 26, 2027				
<u>DESIRUDIN RECOMBINANT - IPRIVASK</u>						
N021271 001	6103515	Aug 15, 2017	DS			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 007	>A> 5837284	Dec 04, 2015	DP		>A> D-121	Oct 23, 2012
	>A> 5908850	Dec 04, 2015	DP U-678		>A> M-80	Oct 17, 2011
	>A> 6228398	Nov 01, 2019	DP U-676			
	>A> 6355656	Dec 04, 2015	DP			
	>A> 6528530	Dec 04, 2015	DP			
	>A> 6635284	Dec 04, 2015	DP U-677			
	>A> 6730325	Nov 01, 2019	DP U-676			
	>A> 7431944	Dec 04, 2015	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 008	>A> 5837284	Dec 04, 2015	DP		>A> D-121	Oct 23, 2012
	>A> 5908850	Dec 04, 2015	DP U-678		>A> M-80	Oct 17, 2011
	>A> 6228398	Nov 01, 2019	DP U-676			
	>A> 6355656	Dec 04, 2015	DP			
	>A> 6528530	Dec 04, 2015	DP			
	>A> 6635284	Dec 04, 2015	DP U-677			
	>A> 6730325	Nov 01, 2019	DP U-676			
	>A> 7431944	Dec 04, 2015	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	7884095	Feb 24, 2029	U-1111			
	>A> 7939518	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N021005 001	5929048	Jun 17, 2014	U-402			
	5985850	Aug 11, 2015	DP			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	6133251	Oct 25, 2016	DP U-828	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-1	Y		
	6884793	Oct 25, 2016	DP	Y		
<u>DORIPENEM - DORIBAX</u>						
N022106 001	5317016	Jun 05, 2015	DS DP U-282			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	7915307	Aug 24, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	7915307	Aug 24, 2027	U-620			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	7547719	Jul 13, 2025	DS DP U-930			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001					>A> NPP	Feb 27, 2011
					>A> PED	Aug 27, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002					>A> NPP	Feb 27, 2011
					>A> PED	Aug 27, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N022101	001				>A> M-86 >A> PED	Jun 18, 2012 Dec 18, 2012
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511	001	5714504	Feb 03, 2015	DP	U-1053	
		5714504*PED	Aug 03, 2015			
		5900424	May 04, 2016	DS	U-1053	
		5900424*PED	Nov 04, 2016			
		6369085	May 25, 2018	DS DP	U-1053	
		6369085*PED	Nov 25, 2018			
		6875872	May 27, 2014	DS		
		6875872*PED	Nov 27, 2014			
		7411070	May 25, 2018	DS	U-1053	
		7411070*PED	Nov 25, 2018			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511	002	5714504	Feb 03, 2015	DP	U-1053	
		5714504*PED	Aug 03, 2015			
		5900424	May 04, 2016	DS	U-1053	
		5900424*PED	Nov 04, 2016			
		6369085	May 25, 2018	DS DP	U-1053	
		6369085*PED	Nov 25, 2018			
		6875872	May 27, 2014	DS		
		6875872*PED	Nov 27, 2014			
		7411070	May 25, 2018	DS	U-1053	
		7411070*PED	Nov 25, 2018			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N022262	001	7855190	Dec 05, 2028		U-1	
		7858605	Jun 23, 2023	DP		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840	001	7855190	Dec 05, 2028		U-1	
		7858605	Jun 23, 2023	DP		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N022573	001	5552394	Jul 22, 2014		U-828	
		6667050	Apr 06, 2019	DP	U-828	
<u>ETRAVIRINE - INTELENCE</u>						
N022187	001	7887845	Mar 25, 2019	DP		
<u>ETRAVIRINE - INTELENCE</u>						
N022187	002	6878717	Nov 05, 2019		U-1016	NCE Jan 18, 2013
		7037917	Nov 05, 2019	DS DP	U-1016	
		7887845	Mar 25, 2019	DP		
<u>EVEROLIMUS - AFINITOR</u>						
N022334	001				>A> I-638 ODE	May 05, 2014 Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334	002				>A> I-638 ODE	May 05, 2014 Oct 29, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334	003				>A> I-638 NCE ODE	May 05, 2014 Mar 30, 2014 Oct 29, 2017
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773	001	5424286	Dec 01, 2016	U-653		
		5424286	Dec 01, 2016	U-1108		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773	002	5424286	Dec 01, 2016	U-653		
		5424286	Dec 01, 2016	U-1108		
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	001				M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	002				M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	003				M-98	Jan 31, 2014
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519	001				NC	Apr 23, 2014
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695	001	7863331	Aug 08, 2020	U-1107		
		7863331	Aug 08, 2020	U-1106		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695	003	7863331	Aug 08, 2020	U-1107		
		7863331	Aug 08, 2020	U-1106		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418	001	7915247	Aug 20, 2027	U-1061		
		7915247	Aug 20, 2027	U-1059		
		7915247	Aug 20, 2027	U-1000		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418	002	7915247	Aug 20, 2027	U-1061		
		7915247	Aug 20, 2027	U-1059		
		7915247	Aug 20, 2027	U-1000		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	001	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	002	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	003	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	7871597	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	>A> 7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	>A> 7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE</u>						
A079043 001					PC	Jul 27, 2011
<u>FIDAXOMICIN - DIFICID</u>						
N201699 001					>A> NCE	May 27, 2016
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	7915243	Mar 22, 2026	DP			
	>A> 7939516	May 04, 2025	DP			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			>A> M-103	May 17, 2014
	7456160	Jan 09, 2021	U-596		>A> PED	Nov 17, 2014
	7456160*PED	Jul 09, 2021			PED	Mar 09, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - GABAPENTIN</u>						
A078974	001				PC	Aug 22, 2011
<u>GABAPENTIN - GRALISE</u>						
N022544	001	6340475	Sep 19, 2016	DP	NP	Jan 28, 2014
		6488962	Jun 20, 2020	DP		
		6635280	Sep 19, 2016	DP		
		6723340	Oct 25, 2021	DP		
		7438927	Feb 26, 2024	U-1114		
		7731989	Oct 25, 2022	DP		
<u>GABAPENTIN - GRALISE</u>						
N022544	002	6340475	Sep 19, 2016	DP	NP	Jan 28, 2014
		6488962	Jun 20, 2020	DP		
		6635280	Sep 19, 2016	DP		
		6723340	Oct 25, 2021	DP		
		7438927	Feb 26, 2024	U-1114		
		7731989	Oct 25, 2022	DP		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399	001	6818787	Nov 06, 2022	DS DP	NCE	Apr 06, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277	001	5980864	Nov 09, 2016	DS DP U-1119	NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277	002	5980864	Nov 09, 2016	DS DP U-1119	NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277	003	5980864	Nov 09, 2016	DS DP U-1119	NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277	004	5980864	Nov 09, 2016	DS DP U-1119	NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277	005	5980864	Nov 09, 2016	DS DP U-1119	NCE	Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711	001	5362475	Nov 08, 2011	DS		
		6676929	May 26, 2015	DP		
		7011815	Feb 01, 2015	U-1112		
		7060250	May 26, 2015	DS		
		7229606	May 26, 2015	U-1112		
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711	002	5362475	Nov 08, 2011	DS		
		6676929	May 26, 2015	DP		
		7011815	Feb 01, 2015	U-1112		
		7060250	May 26, 2015	DS		
		7229606	May 26, 2015	U-1112		
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983	001				PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983	002				PC	Jul 24, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A079183	001				PC	May 14, 2011
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239	001				M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239	002				M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239	003				M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239	004				M-102	Apr 29, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037	001				I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037	002				I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037	003				I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037	004				I-635	Feb 25, 2014
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041	001	5834448	Nov 14, 2016	DP	ODE	Dec 15, 2013
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N021945	001				ODE	Feb 03, 2018
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903	001	>A> 6342530	Nov 14, 2020	DP U-794		
		>A> 6342530	Nov 14, 2020	DP U-1127		
		>A> 6344479	Mar 20, 2021	DS DP U-794	Y	
<u>IMIQUIMOD - ZYCLARA</u>						
N022483	001				I-636	Mar 24, 2014
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N020314	001	>A> 5384113	Jan 24, 2012	DP		
		>A> 5753627	May 19, 2015	U-1125		
		>A> 5776894	Jul 07, 2015	DS DP		
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081	001	7918833	Sep 23, 2027	DP		
		7918833*PED	Mar 23, 2028			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629	003	7918833	Sep 23, 2027	DP		
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R</u>						
N018780	001				NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R PEN</u>						
N018780	005				NR	Mar 25, 2014
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454	001				NCE	Jan 14, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 001	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 002	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 003	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 004	7919115	Jan 04, 2029	DS DP			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	7855217	Nov 24, 2024	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	7855217	Nov 24, 2024	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	7855217	Nov 24, 2024	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001					>A> I-637	Apr 29, 2014
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	6500829	Dec 31, 2019	DS DP		>A> I-637 ODE	Apr 29, 2014 Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	6500829	Dec 31, 2019	DS DP		>A> I-637 ODE	Apr 29, 2014 Mar 07, 2015
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	>A> 6303661	Apr 24, 2017	U-774		>A> NCE	May 20, 2016
	>A> 6890898	Feb 02, 2019	U-493			
	>A> 7078381	Feb 02, 2019	U-493			
	>A> 7407955	Aug 12, 2023	DS DP			
	>A> 7459428	Feb 02, 2019	U-493			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N200738 001					NDF PED	Apr 15, 2014 Oct 15, 2014
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 001	>A> 6080428	May 27, 2017	U-1133			
	>A> 6080428	May 27, 2017	U-1134			
	>A> 6080428	May 27, 2017	U-447			
	>A> 6080428	May 27, 2017	U-1132			
	>A> 6129930	Sep 20, 2013	DP U-1132			
	>A> 6129930	Sep 20, 2013	DP U-1133			
	>A> 6129930	Sep 20, 2013	DP U-1134			
	>A> 6129930	Sep 20, 2013	DP U-448			
	>A> 6469035	Mar 15, 2018	U-768			
	>A> 6469035	Mar 15, 2018	U-1129			
	>A> 6469035	Mar 15, 2018	U-1131			
	>A> 6469035	Mar 15, 2018	U-1130			
	>A> 6676967	Sep 20, 2013	U-1132			
	>A> 6676967	Sep 20, 2013	U-1133			
	>A> 6676967	Sep 20, 2013	U-1134			
	>A> 6676967	Sep 20, 2013	U-548			
	>A> 6746691	Sep 20, 2013	DP U-586			
	>A> 7011848	Sep 20, 2013	U-712			
	>A> 7011848	Sep 20, 2013	U-1135			
	>A> 7011848	Sep 20, 2013	U-1136			
	>A> 7011848	Sep 20, 2013	U-1137			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 002	>A> 6080428	May 27, 2017	U-1133			
	>A> 6080428	May 27, 2017	U-1134			
	>A> 6080428	May 27, 2017	U-447			
	>A> 6080428	May 27, 2017	U-1132			
	>A> 6129930	Sep 20, 2013	DP U-1132			
	>A> 6129930	Sep 20, 2013	DP U-1133			
	>A> 6129930	Sep 20, 2013	DP U-1134			
	>A> 6129930	Sep 20, 2013	DP U-448			
	>A> 6469035	Mar 15, 2018	U-768			
	>A> 6469035	Mar 15, 2018	U-1129			
	>A> 6469035	Mar 15, 2018	U-1131			
	>A> 6469035	Mar 15, 2018	U-1130			
	>A> 6676967	Sep 20, 2013	U-1132			
	>A> 6676967	Sep 20, 2013	U-1133			
	>A> 6676967	Sep 20, 2013	U-1134			
	>A> 6676967	Sep 20, 2013	U-548			
	>A> 6746691	Sep 20, 2013	DP U-586			
	>A> 7011848	Sep 20, 2013	U-712			
	>A> 7011848	Sep 20, 2013	U-1135			
	>A> 7011848	Sep 20, 2013	U-1136			
	>A> 7011848	Sep 20, 2013	U-1137			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 003	>A> 6080428	May 27, 2017	U-1133			
	>A> 6080428	May 27, 2017	U-1134			
	>A> 6080428	May 27, 2017	U-447			
	>A> 6080428	May 27, 2017	U-1132			
	>A> 6129930	Sep 20, 2013	DP U-1132			
	>A> 6129930	Sep 20, 2013	DP U-1133			
	>A> 6129930	Sep 20, 2013	DP U-1134			
	>A> 6129930	Sep 20, 2013	DP U-448			
	>A> 6469035	Mar 15, 2018	U-768			
	>A> 6469035	Mar 15, 2018	U-1129			
	>A> 6469035	Mar 15, 2018	U-1131			
	>A> 6469035	Mar 15, 2018	U-1130			
	>A> 6676967	Sep 20, 2013	U-1132			
	>A> 6676967	Sep 20, 2013	U-1133			
	>A> 6676967	Sep 20, 2013	U-1134			
	>A> 6676967	Sep 20, 2013	U-548			
	>A> 6746691	Sep 20, 2013	DP U-586			
	>A> 7011848	Sep 20, 2013	U-712			
	>A> 7011848	Sep 20, 2013	U-1135			
	>A> 7011848	Sep 20, 2013	U-1136			
	>A> 7011848	Sep 20, 2013	U-1137			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 004	>A> 6080428	May 27, 2017	U-1133			
	>A> 6080428	May 27, 2017	U-1134			
	>A> 6080428	May 27, 2017	U-447			
	>A> 6080428	May 27, 2017	U-1132			
	>A> 6129930	Sep 20, 2013	DP U-1132			
	>A> 6129930	Sep 20, 2013	DP U-1133			
	>A> 6129930	Sep 20, 2013	DP U-1134			
	>A> 6129930	Sep 20, 2013	DP U-448			
	>A> 6469035	Mar 15, 2018	U-768			
	>A> 6469035	Mar 15, 2018	U-1129			
	>A> 6469035	Mar 15, 2018	U-1131			
	>A> 6469035	Mar 15, 2018	U-1130			
	>A> 6676967	Sep 20, 2013	U-1132			
	>A> 6676967	Sep 20, 2013	U-1133			
	>A> 6676967	Sep 20, 2013	U-1134			
	>A> 6676967	Sep 20, 2013	U-548			
	>A> 6746691	Sep 20, 2013	DP U-586			
	>A> 7011848	Sep 20, 2013	U-712			
	>A> 7011848	Sep 20, 2013	U-1135			
	>A> 7011848	Sep 20, 2013	U-1136			
	>A> 7011848	Sep 20, 2013	U-1137			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 001	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 002	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
<u>METRONIDAZOLE - VANDAZOLE</u>						
N021806 001	7456207	Sep 22, 2024	DP			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	7888342	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	7888342	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	7888342	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	7888342	Nov 05, 2021	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	7919483	Feb 28, 2027	U-1078			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	7919483	Feb 28, 2027	U-1078			
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001					M-99	Jan 19, 2014
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428 001	7671070*PED	Mar 29, 2020				
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050746 001	6025389	Oct 20, 2014	DP U-1122			
<u>NALTREXONE - VIVITROL</u>						
N021897 001	>A> 7919499	Oct 15, 2029	U-1124			
	>A> 7919499	Oct 15, 2029	U-1123			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 002	>A> 6080428	May 27, 2017	U-1139			
	>A> 6080428	May 27, 2017	U-1140			
	>A> 6080428	May 27, 2017	U-1141			
	>A> 6080428	May 27, 2017	U-331			
	>A> 6080428	May 27, 2017	U-1138			
	>A> 6129930	Sep 20, 2013	DP U-1138			
	>A> 6129930	Sep 20, 2013	DP U-1139			
	>A> 6129930	Sep 20, 2013	DP U-1140			
	>A> 6129930	Sep 20, 2013	DP U-1141			
	>A> 6129930	Sep 20, 2013	DP U-354			
	>A> 6406715	Sep 20, 2013	DP U-450			
	>A> 6469035	Mar 15, 2018	U-1145			
	>A> 6469035	Mar 15, 2018	U-1142			
	>A> 6469035	Mar 15, 2018	U-1144			
	>A> 6469035	Mar 15, 2018	U-768			
	>A> 6469035	Mar 15, 2018	U-1143			
	>A> 6676967	Sep 20, 2013	U-1138			
	>A> 6676967	Sep 20, 2013	U-1139			
	>A> 6676967	Sep 20, 2013	U-1140			
	>A> 6676967	Sep 20, 2013	U-1146			
	>A> 6676967	Sep 20, 2013	U-548			
	>A> 6746691	Sep 20, 2013	DP U-586			
	>A> 7011848	Sep 20, 2013	U-712			
	>A> 7011848	Sep 20, 2013	U-1140			
	>A> 7011848	Sep 20, 2013	U-1141			
	>A> 7011848	Sep 20, 2013	U-1147			
	>A> 7011848	Sep 20, 2013	U-1148			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 003	>A> 6080428	May 27, 2017	U-1139			
	>A> 6080428	May 27, 2017	U-1140			
	>A> 6080428	May 27, 2017	U-1141			
	>A> 6080428	May 27, 2017	U-331			
	>A> 6080428	May 27, 2017	U-1138			
	>A> 6129930	Sep 20, 2013	DP U-1138			
	>A> 6129930	Sep 20, 2013	DP U-1139			
	>A> 6129930	Sep 20, 2013	DP U-1140			
	>A> 6129930	Sep 20, 2013	DP U-1141			
	>A> 6129930	Sep 20, 2013	DP U-354			
	>A> 6406715	Sep 20, 2013	DP U-450			
	>A> 6469035	Mar 15, 2018	U-1145			
	>A> 6469035	Mar 15, 2018	U-1142			
	>A> 6469035	Mar 15, 2018	U-1144			
	>A> 6469035	Mar 15, 2018	U-768			
	>A> 6469035	Mar 15, 2018	U-1143			
	>A> 6676967	Sep 20, 2013	U-1138			
	>A> 6676967	Sep 20, 2013	U-1139			
	>A> 6676967	Sep 20, 2013	U-1140			
	>A> 6676967	Sep 20, 2013	U-1141			
	>A> 6676967	Sep 20, 2013	U-1146			
	>A> 6676967	Sep 20, 2013	U-548			
	>A> 6746691	Sep 20, 2013	DP U-586			
	>A> 7011848	Sep 20, 2013	U-712			
	>A> 7011848	Sep 20, 2013	U-1140			
	>A> 7011848	Sep 20, 2013	U-1141			
	>A> 7011848	Sep 20, 2013	U-1147			
	>A> 7011848	Sep 20, 2013	U-1148			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 004	>A> 6080428	May 27, 2017	U-1139			
	>A> 6080428	May 27, 2017	U-1140			
	>A> 6080428	May 27, 2017	U-1141			
	>A> 6080428	May 27, 2017	U-331			
	>A> 6080428	May 27, 2017	U-1138			
	>A> 6129930	Sep 20, 2013	DP U-1138			
	>A> 6129930	Sep 20, 2013	DP U-1139			
	>A> 6129930	Sep 20, 2013	DP U-1140			
	>A> 6129930	Sep 20, 2013	DP U-1141			
	>A> 6129930	Sep 20, 2013	DP U-354			
	>A> 6406715	Sep 20, 2013	DP U-450			
	>A> 6469035	Mar 15, 2018	U-1145			
	>A> 6469035	Mar 15, 2018	U-1142			
	>A> 6469035	Mar 15, 2018	U-1144			
	>A> 6469035	Mar 15, 2018	U-768			
	>A> 6469035	Mar 15, 2018	U-1143			
	>A> 6676967	Sep 20, 2013	U-1138			
	>A> 6676967	Sep 20, 2013	U-1139			
	>A> 6676967	Sep 20, 2013	U-1140			
	>A> 6676967	Sep 20, 2013	U-1141			
	>A> 6676967	Sep 20, 2013	U-1146			
	>A> 6676967	Sep 20, 2013	U-548			
	>A> 6746691	Sep 20, 2013	DP U-586			
	>A> 7011848	Sep 20, 2013	U-712			
	>A> 7011848	Sep 20, 2013	U-1140			
	>A> 7011848	Sep 20, 2013	U-1141			
	>A> 7011848	Sep 20, 2013	U-1147			
	>A> 7011848	Sep 20, 2013	U-1148			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 001	>A> 6080428	May 27, 2017	U-862			
	>A> 6080428	May 27, 2017	U-1134			
	>A> 6080428	May 27, 2017	U-1132			
	>A> 6129930	Sep 20, 2013	DP U-862			
	>A> 6129930	Sep 20, 2013	DP U-1134			
	>A> 6129930	Sep 20, 2013	DP U-1132			
	>A> 6469035	Mar 15, 2018	U-863			
	>A> 6469035	Mar 15, 2018	U-1149			
	>A> 6469035	Mar 15, 2018	U-1129			
	>A> 6676967	Sep 20, 2013	U-862			
	>A> 6676967	Sep 20, 2013	U-1134			
	>A> 6676967	Sep 20, 2013	U-1132			
	>A> 7011848	Sep 20, 2013	U-862			
	>A> 7011848	Sep 20, 2013	U-1151			
	>A> 7011848	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 002	>A> 6080428	May 27, 2017	U-862			
	>A> 6080428	May 27, 2017	U-1134			
	>A> 6080428	May 27, 2017	U-1132			
	>A> 6129930	Sep 20, 2013	DP U-862			
	>A> 6129930	Sep 20, 2013	DP U-1134			
	>A> 6129930	Sep 20, 2013	DP U-1132			
	>A> 6469035	Mar 15, 2018	U-863			
	>A> 6469035	Mar 15, 2018	U-1149			
	>A> 6469035	Mar 15, 2018	U-1129			
	>A> 6676967	Sep 20, 2013	U-862			
	>A> 6676967	Sep 20, 2013	U-1134			
	>A> 6676967	Sep 20, 2013	U-1132			
	>A> 7011848	Sep 20, 2013	U-862			
	>A> 7011848	Sep 20, 2013	U-1151			
	>A> 7011848	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 003	>A> 6080428	May 27, 2017	U-862			
	>A> 6080428	May 27, 2017	U-1134			
	>A> 6080428	May 27, 2017	U-1132			
	>A> 6129930	Sep 20, 2013	DP U-862			
	>A> 6129930	Sep 20, 2013	DP U-1134			
	>A> 6129930	Sep 20, 2013	DP U-1132			
	>A> 6469035	Mar 15, 2018	U-863			
	>A> 6469035	Mar 15, 2018	U-1149			
	>A> 6469035	Mar 15, 2018	U-1129			
	>A> 6676967	Sep 20, 2013	U-862			
	>A> 6676967	Sep 20, 2013	U-1134			
	>A> 6676967	Sep 20, 2013	U-1132			
	>A> 7011848	Sep 20, 2013	U-862			
	>A> 7011848	Sep 20, 2013	U-1151			
	>A> 7011848	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 004	>A> 6080428	May 27, 2017	U-862			
	>A> 6080428	May 27, 2017	U-1134			
	>A> 6080428	May 27, 2017	U-1132			
	>A> 6469035	Mar 15, 2018	U-863			
	>A> 6469035	Mar 15, 2018	U-1149			
	>A> 6469035	Mar 15, 2018	U-1129			
	>A> 6676967	Sep 20, 2013	U-862			
	>A> 6676967	Sep 20, 2013	U-1134			
	>A> 6676967	Sep 20, 2013	U-1132			
	>A> 7011848	Sep 20, 2013	U-862			
	>A> 7011848	Sep 20, 2013	U-1151			
	>A> 7011848	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 005	>A> 6080428	May 27, 2017	U-862			
	>A> 6080428	May 27, 2017	U-1134			
	>A> 6080428	May 27, 2017	U-1132			
	>A> 6469035	Mar 15, 2018	U-863			
	>A> 6469035	Mar 15, 2018	U-1149			
	>A> 6469035	Mar 15, 2018	U-1129			
	>A> 6676967	Sep 20, 2013	U-862			
	>A> 6676967	Sep 20, 2013	U-1134			
	>A> 6676967	Sep 20, 2013	U-1132			
	>A> 7011848	Sep 20, 2013	U-862			
	>A> 7011848	Sep 20, 2013	U-1151			
	>A> 7011848	Sep 20, 2013	U-1150			
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 001					>A> NPP	Dec 04, 2012
					>A> PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 002					>A> NPP	Dec 04, 2012
					>A> PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 003					>A> NPP	Dec 04, 2012
					>A> PED	Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 004					>A> NPP	Dec 04, 2012
					>A> PED	Jun 04, 2013
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001	5763483	Dec 27, 2016	DS	U-376		
	5763483	Dec 27, 2016	DS	U-1113		
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	7923536	Dec 09, 2023	U-1117			
	RE41884	Aug 14, 2016	U-1117			
<u>PALIPERIDONE - INVEGA</u>						
N021999 001					NPP	Apr 06, 2014
					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 002					NPP	Apr 06, 2014
					PED	Oct 06, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE - INVEGA</u>						
N021999 003					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 004					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 006					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 001	>A> 7947724	Jan 30, 2024	DP			
	>A> 7947725	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 002	>A> 7947724	Jan 30, 2024	DP			
	>A> 7947725	Jan 30, 2024	DP			
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>						
A091427 001					PC	Nov 01, 2011
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PERFLUTREN - DEFINITY</u>						
N021064 001	5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	7915229	Apr 14, 2023	DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2013	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 03, 2023	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RANOLAZINE - RANEXA</u>						
N021526 001	6369062	May 27, 2019	DP	Y		
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	>A> 6838464	Feb 26, 2021	DS DP		>A> NCE	May 20, 2016
	>A> 7067522	Dec 20, 2019	DS DP			
	>A> 7125879	Apr 14, 2023	DS DP U-1153			
	>A> 7638522	Apr 14, 2023	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Feb 11, 2014		Y		
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Feb 11, 2014		Y		
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Feb 11, 2014	U-240	Y		
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Feb 11, 2014	U-240	Y		
<u>ROFLUMILAST - DALIRESP</u>						
N022522 001	5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 001	>A> 7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 002	>A> 7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 003	>A> 7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 004	>A> 7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 005	>A> 7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 006	>A> 7927624	Dec 02, 2021	DP U-20			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	6699498	Nov 27, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	6699498	Nov 27, 2020	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	6699498	Nov 27, 2020	DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Aug 17, 2020	DS DP		NCE ODE	Nov 14, 2013 Nov 14, 2015
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N201444 001					ODE	Jan 14, 2018
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	7668730	Jun 16, 2024		U-1110		
	7895059	Dec 17, 2022		U-1110		
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N021923 001	7897623	Jan 12, 2020	DP			
<u>SPINOSAD - NATROBA</u>						
N022408 001	5496931	Mar 05, 2013	DS	U-1105	NCE	Jan 18, 2016
	6063771	Jun 22, 2019		DP U-1105		
	6342482	Jun 22, 2019		DP U-1105		
	7030095	Jul 02, 2021		DP U-1105		
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	>A> 7776007	Nov 28, 2026		DP		
	7901385	Jul 31, 2026		DP		
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 001					>A> I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 002					>A> I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 003					>A> I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 004					>A> I-639	May 20, 2014
<u>TECHNETIUM TC-99M MERTIATIDE KIT - TECHNESCAN MAG3</u>						
N019882 001	>A> 5573748	Nov 12, 2013	DP			
<u>TELAPREVIR - INCIVEK</u>						
N201917 001					>A> NCE	May 23, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001	7858594	Sep 11, 2023	DS DP	U-999		
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 001	>A> 6503894	Aug 30, 2020		U-1103	NP	Apr 29, 2014
<u>TESTOSTERONE - FORTESTA</u>						
N021463 001	6319913	Nov 09, 2018		U-490		
	6579865	Nov 09, 2018		DP		
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	>A> 7935690	Apr 21, 2023		U-1009		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	7879828	Feb 05, 2029	DP			
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	>A> 6908928	Sep 24, 2021	DS DP U-762			
	>A> 6908928	Sep 24, 2021	DS DP U-566			
	>A> 7309707	Sep 24, 2021	DS DP			
	>A> 7694676	Mar 12, 2027	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	>A> 7947739	Mar 04, 2025	DP			
<u>VANDETANIB - VANDETANIB</u>						
N022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	>A> RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
<u>VANDETANIB - VANDETANIB</u>						
N022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	>A> RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817 001	>A> 7932241	Feb 05, 2028	DP			
	>A> 7932241*PED	Aug 05, 2028				
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>